Strict	O
control	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
replication	O
by	O
a	O
genetic	O
switch	O
:	O
Tet	O
for	O
Tat	O
.	O

Live-attenuated	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
variants	O
have	O
shown	O
great	O
promise	O
as	O
AIDS	O
vaccines	O
,	O
but	O
continued	O
replication	O
can	O
lead	O
to	O
the	O
selection	O
of	O
faster-replicating	O
variants	O
that	O
are	O
pathogenic	O
.	O

We	O
therefore	O
designed	O
HIV-1	B-DNA
genomes	I-DNA
that	O
replicate	O
exclusively	O
upon	O
addition	O
of	O
the	O
nontoxic	O
effector	O
doxycycline	O
(	O
dox	O
)	O
.	O

This	O
was	O
achieved	O
by	O
replacement	O
of	O
the	O
viral	O
TAR-Tat	O
system	O
for	O
transcriptional	O
activation	O
by	O
the	O
Escherichia	O
coli-derived	O
Tet	O
system	O
for	O
inducible	O
gene	O
expression	O
.	O

These	O
designer	O
``	O
HIV-rtTA	O
''	O
viruses	O
replicate	O
in	O
a	O
strictly	O
dox-dependent	O
manner	O
both	O
in	O
a	O
T-cell	B-cell_line
line	I-cell_line
and	O
in	O
primary	B-cell_type
blood	I-cell_type
cells	I-cell_type
,	O
and	O
the	O
rate	O
of	O
replication	O
can	O
be	O
fine-tuned	O
by	O
simple	O
variation	O
of	O
the	O
dox	O
concentration	O
.	O

These	O
HIV-rtTA	O
viruses	O
provide	O
a	O
tool	O
to	O
perform	O
genetics	O
,	O
e.g.	O
,	O
selection	O
and	O
optimization	O
experiments	O
,	O
with	O
the	O
E.	O
coli-derived	O
Tet	O
reagents	O
in	O
a	O
eukaryotic	O
background	O
.	O

Furthermore	O
,	O
such	O
viruses	O
may	O
represent	O
improved	O
vaccine	O
candidates	O
because	O
their	O
replication	O
can	O
be	O
turned	O
on	O
and	O
off	O
at	O
will	O
.	O

JOURNAL	NULL
OF	NULL
VIROLOGY	NULL
,	NULL
Jan.	NULL
2001	NULL
,	NULL
p.	NULL
979-987	NULL
0022-538X/01/	NULL
$	NULL
04.00+0	NULL
-	NULL
DOI	NULL
:	NULL
10.1128/JV1.75.2.979-987.2001	NULL
Vol	NULL
.	NULL

75	NULL
,	NULL
No	NULL
.	NULL

2	NULL
Copyright	NULL
Â©	NULL
2001	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
.	NULL

All	NULL
Rights	NULL
Reserved	NULL
.	NULL

Strict	NULL
Control	NULL
of	NULL
Human	NULL
Immunodeficiency	NULL
Virus	NULL
Type	NULL
1	NULL
Replication	NULL
by	NULL
a	NULL
Genetic	NULL
Switch	NULL
:	NULL
Tet	NULL
for	NULL
Tat	NULL
KOEN	NULL
VERHOEF	NULL
,	NULL
'	NULL
{	NULL
GIUSEPPE	NULL
MARZIO	NULL
,	NULL
!	NULL

WOLFGANG	NULL
HILLEN	NULL
,	NULL
*	NULL
HERMANN	NULL
BUJARD	NULL
,	NULL
*	NULL
Anp	NULL
BEN	NULL
BERKHOUT'*	NULL
Department	NULL
of	NULL
Human	NULL
Retrovirology	NULL
,	NULL
Academic	NULL
Medical	NULL
Center	NULL
,	NULL
University	NULL
of	NULL
Amsterdam	NULL
,	NULL
Amsterdam	NULL
,	NULL
The	NULL
Netherlands	NULL
,	NULL
``	NULL
and	NULL
Friedrich-Alexander	NULL
University	NULL
,	NULL
Erlangen	NULL
,	NULL
``	NULL
and	NULL
Zentrum	NULL
fiir	NULL
Molekulare	NULL
Biologie	NULL
,	NULL
University	NULL
of	NULL
Heidelberg	NULL
,	NULL
Heidelberg	NULL
,	NULL
*	NULL
Germany	NULL
Received	NULL
25	NULL
July	NULL
2000/Accepted	NULL
11	NULL
October	NULL
2000	NULL
Live-attenuated	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HIV-1	NULL
)	NULL
variants	NULL
have	NULL
shown	NULL
great	NULL
promise	NULL
as	NULL
AIDS	NULL
vaccines	NULL
,	NULL
but	NULL
continued	NULL
replication	NULL
can	NULL
lead	NULL
to	NULL
the	NULL
selection	NULL
of	NULL
faster-replicating	NULL
variants	NULL
that	NULL
are	NULL
pathogenic	NULL
.	NULL

We	NULL
therefore	NULL
designed	NULL
HIV-1	NULL
genomes	NULL
that	NULL
replicate	NULL
exclusively	NULL
upon	NULL
addition	NULL
of	NULL
the	NULL
nontoxic	NULL
effector	NULL
doxycycline	NULL
(	NULL
dox	NULL
)	NULL
.	NULL

This	NULL
was	NULL
achieved	NULL
by	NULL
replacement	NULL
of	NULL
the	NULL
viral	NULL
TAR-Tat	NULL
system	NULL
for	NULL
transcriptional	NULL
activation	NULL
by	NULL
the	NULL
Escherichia	NULL
coli-derived	NULL
Tet	NULL
system	NULL
for	NULL
inducible	NULL
gene	NULL
expression	NULL
.	NULL

These	NULL
designer	NULL
``	NULL
HIV-rtTA	NULL
``	NULL
viruses	NULL
replicate	NULL
in	NULL
a	NULL
strictly	NULL
dox-dependent	NULL
manner	NULL
both	NULL
in	NULL
a	NULL
T-cell	NULL
line	NULL
and	NULL
in	NULL
primary	NULL
blood	NULL
cells	NULL
,	NULL
and	NULL
the	NULL
rate	NULL
of	NULL
replication	NULL
can	NULL
be	NULL
fine-tuned	NULL
by	NULL
simple	NULL
variation	NULL
of	NULL
the	NULL
dox	NULL
concentration	NULL
.	NULL

These	NULL
HIV-rtTA	NULL
viruses	NULL
provide	NULL
a	NULL
tool	NULL
to	NULL
perform	NULL
genetics	NULL
,	NULL
e.g	NULL
.	NULL

,	NULL
selection	NULL
and	NULL
optimization	NULL
experiments	NULL
,	NULL
with	NULL
the	NULL
E.	NULL
coli-derived	NULL
Tet	NULL
reagents	NULL
in	NULL
a	NULL
eukaryotic	NULL
background	NULL
.	NULL

Furthermore	NULL
,	NULL
such	NULL
viruses	NULL
may	NULL
represent	NULL
improved	NULL
vaccine	NULL
candidates	NULL
because	NULL
their	NULL
replication	NULL
can	NULL
be	NULL
turned	NULL
on	NULL
and	NULL
off	NULL
at	NULL
will	NULL
.	NULL

Live-attenuated	NULL
virus	NULL
vaccines	NULL
(	NULL
such	NULL
as	NULL
vaccinia	NULL
,	NULL
polio	NULL
,	NULL
and	NULL
measles	NULL
viruses	NULL
)	NULL
have	NULL
been	NULL
enormously	NULL
successful	NULL
and	NULL
have	NULL
made	NULL
a	NULL
dramatic	NULL
and	NULL
historic	NULL
impact	NULL
on	NULL
public	NULL
health	NULL
.	NULL

Replicating	NULL
virus	NULL
vaccines	NULL
also	NULL
demonstrated	NULL
superior	NULL
performance	NULL
in	NULL
AIDS	NULL
vaccine	NULL
trials	NULL
(	NULL
1	NULL
,	NULL
14	NULL
,	NULL
32	NULL
,	NULL
40	NULL
,	NULL
45	NULL
,	NULL
46	NULL
,	NULL
49	NULL
,	NULL
54	NULL
)	NULL
.	NULL

However	NULL
,	NULL
safety	NULL
concerns	NULL
remain	NULL
for	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HIV-1	NULL
)	NULL
about	NULL
either	NULL
the	NULL
reversion	NULL
of	NULL
attenuated	NULL
vaccine	NULL
strains	NULL
to	NULL
virulent	NULL
phenotypes	NULL
or	NULL
the	NULL
induction	NULL
of	NULL
fulmi-nant	NULL
infection	NULL
in	NULL
(	NULL
immunocompromised	NULL
)	NULL
individuals	NULL
.	NULL

Testifying	NULL
to	NULL
the	NULL
genetic	NULL
instability	NULL
of	NULL
such	NULL
strains	NULL
is	NULL
the	NULL
recent	NULL
demonstration	NULL
that	NULL
the	NULL
HIV-1	NULL
A3	NULL
vaccine	NULL
candidate	NULL
,	NULL
which	NULL
contains	NULL
three	NULL
deletions	NULL
in	NULL
nonessential	NULL
parts	NULL
of	NULL
the	NULL
genome	NULL
,	NULL
is	NULL
able	NULL
to	NULL
regain	NULL
full	NULL
replication	NULL
capacity	NULL
within	NULL
4	NULL
months	NULL
of	NULL
replication	NULL
in	NULL
tissue	NULL
culture	NULL
(	NULL
11	NULL
)	NULL
.	NULL

It	NULL
has	NULL
also	NULL
been	NULL
reported	NULL
that	NULL
the	NULL
viral	NULL
load	NULL
of	NULL
attenuated	NULL
simian	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
SIV	NULL
)	NULL
variants	NULL
increased	NULL
after	NULL
several	NULL
years	NULL
in	NULL
some	NULL
infected	NULL
monkeys	NULL
,	NULL
concomitant	NULL
with	NULL
the	NULL
onset	NULL
of	NULL
AIDS	NULL
(	NULL
2	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
although	NULL
there	NULL
is	NULL
some	NULL
evidence	NULL
that	NULL
attenuated	NULL
HIV-1	NULL
variants	NULL
lacking	NULL
the	NULL
nef	NULL
gene	NULL
result	NULL
in	NULL
a	NULL
benign	NULL
course	NULL
of	NULL
infection	NULL
in	NULL
humans	NULL
(	NULL
17	NULL
)	NULL
,	NULL
a	NULL
decline	NULL
in	NULL
CD4*	NULL
T-cell	NULL
numbers	NULL
has	NULL
been	NULL
reported	NULL
recently	NULL
for	NULL
some	NULL
of	NULL
these	NULL
individuals	NULL
,	NULL
which	NULL
is	NULL
an	NULL
early	NULL
sign	NULL
that	NULL
these	NULL
persons	NULL
could	NULL
develop	NULL
AIDS	NULL
(	NULL
20	NULL
,	NULL
25	NULL
)	NULL
.	NULL

To	NULL
improve	NULL
the	NULL
safety	NULL
of	NULL
potential	NULL
HIV-1	NULL
vaccine	NULL
strains	NULL
,	NULL
we	NULL
designed	NULL
an	NULL
HIV-1	NULL
variant	NULL
for	NULL
which	NULL
replication	NULL
depends	NULL
on	NULL
the	NULL
addition	NULL
of	NULL
the	NULL
nontoxic	NULL
,	NULL
selective	NULL
effector	NULL
doxycycline	NULL
(	NULL
dox	NULL
)	NULL
.	NULL

This	NULL
was	NULL
done	NULL
by	NULL
incorporation	NULL
of	NULL
the	NULL
Tet	NULL
system	NULL
for	NULL
inducible	NULL
gene	NULL
expression	NULL
(	NULL
5	NULL
,	NULL
23	NULL
,	NULL
24	NULL
)	NULL
into	NULL
the	NULL
viral	NULL
genome	NULL
.	NULL

This	NULL
system	NULL
is	NULL
based	NULL
on	NULL
two	NULL
elements	NULL
from	NULL
the	NULL
Escherichia	NULL
coli	NULL
tet	NULL
operon	NULL
,	NULL
the	NULL
tetracycline-inducible	NULL
repressor	NULL
protein	NULL
(	NULL
TetR	NULL
)	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
Department	NULL
of	NULL
Human	NULL
Retrovirology	NULL
,	NULL
Academic	NULL
Medical	NULL
Center	NULL
,	NULL
University	NULL
of	NULL
Amsterdam	NULL
,	NULL
Meibergdreef	NULL
15	NULL
,	NULL
1105	NULL
AZ	NULL
Amsterdam	NULL
,	NULL
The	NULL
Netherlands	NULL
.	NULL

Phone	NULL
:	NULL
(	NULL
31-20	NULL
)	NULL
566-5822	NULL
.	NULL

Fax	NULL
:	NULL
(	NULL
31-20	NULL
)	NULL
566-9064	NULL
.	NULL

E-mail	NULL
:	NULL
b.berkhout	NULL
@	NULL
ame.uva.nl	NULL
.	NULL

i	NULL
Present	NULL
address	NULL
:	NULL
Department	NULL
of	NULL
Biochemistry	NULL
,	NULL
University	NULL
of	NULL
Oxford	NULL
,	NULL
Oxford	NULL
,	NULL
England	NULL
.	NULL

979	NULL
that	NULL
has	NULL
been	NULL
converted	NULL
into	NULL
a	NULL
eukaryotic	NULL
transcriptional	NULL
activator	NULL
(	NULL
tTA	NULL
or	NULL
rtTA	NULL
)	NULL
,	NULL
and	NULL
the	NULL
fetO	NULL
operator	NULL
DNA	NULL
sequence	NULL
.	NULL

The	NULL
Tet	NULL
system	NULL
has	NULL
found	NULL
wide	NULL
application	NULL
and	NULL
allows	NULL
strict	NULL
and	NULL
graded	NULL
regulation	NULL
of	NULL
gene	NULL
expression	NULL
in	NULL
many	NULL
experimental	NULL
setups	NULL
,	NULL
for	NULL
example	NULL
,	NULL
in	NULL
the	NULL
breeding	NULL
of	NULL
transgenic	NULL
animals	NULL
and	NULL
in	NULL
gene	NULL
therapy	NULL
approaches	NULL
.	NULL

The	NULL
Tet	NULL
system	NULL
has	NULL
been	NULL
successfully	NULL
used	NULL
to	NULL
regulate	NULL
the	NULL
expression	NULL
of	NULL
transgenes	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
viral	NULL
vector	NULL
systems	NULL
,	NULL
including	NULL
lentiviral	NULL
vectors	NULL
.	NULL

We	NULL
now	NULL
report	NULL
a	NULL
completely	NULL
novel	NULL
strategy	NULL
to	NULL
impose	NULL
control	NULL
over	NULL
HIV-1	NULL
replication	NULL
by	NULL
replacement	NULL
of	NULL
the	NULL
viral	NULL
frams-activator	NULL
protein	NULL
Tat	NULL
and	NULL
its	NULL
binding	NULL
site	NULL
TAR	NULL
by	NULL
the	NULL
two	NULL
components	NULL
of	NULL
the	NULL
Tet	NULL
system	NULL
,	NULL
such	NULL
that	NULL
an	NULL
exogenous	NULL
agent	NULL
(	NULL
dox	NULL
)	NULL
can	NULL
be	NULL
used	NULL
to	NULL
turn	NULL
virus	NULL
replication	NULL
on	NULL
in	NULL
a	NULL
reversible	NULL
manner	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Construction	NULL
of	NULL
the	NULL
HIV-rtTA	NULL
molecular	NULL
clones	NULL
.	NULL

The	NULL
following	NULL
primers	NULL
were	NULL
used	NULL
in	NULL
mutagenesis	NULL
and	NULL
cloning	NULL
:	NULL
BglIINef	NULL
(	NULL
5'-AGCTGTAGATCTTAGCCAC-3	NULL
'	NULL
,	NULL
sense	NULL
)	NULL
,	NULL
deltaU3	NULL
TAGAGTGGAGGT-3	NULL
'	NULL
,	NULL
sense	NULL
)	NULL
,	NULL
Sp6BspEI	NULL
(	NULL
5'-A4TTTAGGTGACACTATAGGT	NULL
ACTCCGGATGCAGCTCTCG-3	NULL
'	NULL
,	NULL
antisense	NULL
)	NULL
,	NULL
TARBI23L13	NULL
(	NULL
5	NULL
``	NULL
-CCAGAGA	NULL
GCTCCAATGCTCCTTTCTGGTCTAACCAGAGAGACC-3	NULL
'	NULL
,	NULL
antisense	NULL
)	NULL
,	NULL
XemldeltaNef	NULL
(	NULL
5	NULL
%	NULL
-GCTTGGAAAGGATTITTGCTATAACCATGTCTAGACT	NULL
GG-deletion-CCAGTCACACCTCAGGTACC-3	NULL
'	NULL
,	NULL
sense	NULL
)	NULL
,	NULL
BamHIEny	NULL
(	NULL
5	NULL
``	NULL
-GAA	NULL
CTAGTGGATCCTTAGCACTTATC-3	NULL
'	NULL
,	NULL
sense	NULL
)	NULL
,	NULL
Smalanti-Nef	NULL
(	NULL
5-TCCCCCG	NULL
GGGTGGCTAAGATCTACAGCTGC-3	NULL
'	NULL
,	NULL
antisense	NULL
)	NULL
,	NULL
Anti-UBatt	NULL
(	NULL
5'-GGAGT	NULL
GAATTAGCCCTTCCA-3	NULL
'	NULL
,	NULL
antisense	NULL
)	NULL
,	NULL
SallSpl	NULL
TACAA-deletion-GTCGACAGGGAGGCGTGGCCTG-3	NULL
'	NULL
,	NULL
sense	NULL
)	NULL
,	NULL
xBSallSpl	NULL
sense	NULL
)	NULL
,	NULL
SpÃ©anti-lue	NULL
(	NULL
55-ATTTAGGTGACACTATAGGCAGTTGCTCTCCAGC	NULL
GGTTCC-3	NULL
'	NULL
,	NULL
antisense	NULL
)	NULL
,	NULL
KB12-	NULL
(	NULL
5-CTGGAAAGTCCCCAGCGGAAAGTC	NULL
CCIT-3	NULL
'	NULL
,	NULL
antisense	NULL
)	NULL
,	NULL
M13reverse	NULL
(	NULL
5'-AGGAAACAGCTATGACCAT-3	NULL
'	NULL
,	NULL
sense	NULL
)	NULL
,	NULL
and	NULL
ExtN4Not	NULL
(	NULL
5-NNCGCCGGCGACTCAAGGCAAGCTTTATTGAGGCT	NULL
TAAG-3	NULL
'	NULL
,	NULL
antisense	NULL
)	NULL
.	NULL

Changes	NULL
compared	NULL
with	NULL
the	NULL
sequence	NULL
of	NULL
LAI	NULL
are	NULL
marked	NULL
as	NULL
follows	NULL
:	NULL
insertions	NULL
are	NULL
underlined	NULL
,	NULL
substitutions	NULL
are	NULL
in	NULL
boldface	NULL
,	NULL
deletions	NULL
are	NULL
denoted	NULL
as	NULL
such	NULL
,	NULL
and	NULL
non-template	NULL
5	NULL
'	NULL
extensions	NULL
are	NULL
shown	NULL
in	NULL
italics	NULL
.	NULL

The	NULL
following	NULL
tetO	NULL
motif	NULL
was	NULL
used	NULL
:	NULL
5'-CTCGAGTTTACCACTCCCTATCA	NULL
GTGATAGAGAAAAGTGAAAGTCGAC-3	NULL
'	NULL
and	NULL
3'-GAGCTCAAATGGTG	NULL
AGGGATAGTCACTATCTCTTTTCACTTTCAGCTG-5	NULL
'	NULL
.	NULL

The	NULL
sequence	NULL
of	NULL
a	NULL
single	NULL
fefO	NULL
double-stranded	NULL
DNA	NULL
site	NULL
is	NULL
shown	NULL
(	NULL
underlined	NULL
)	NULL
,	NULL
flanked	NULL
by	NULL
XhoI	NULL
and	NULL
Sall	NULL
restriction	NULL
sites	NULL
.	NULL

The	NULL
dimeric	NULL
,	NULL
tetrameric	NULL
,	NULL
and	NULL
hexameric	NULL
fefO	NULL
linkers	NULL
980	NULL
VERHOEF	NULL
ET	NULL
AL	NULL
.	NULL

were	NULL
generated	NULL
by	NULL
Xhol/Sall	NULL
digestion	NULL
and	NULL
subsequent	NULL
ligation	NULL
of	NULL
the	NULL
compatible	NULL
sticky	NULL
ends	NULL
.	NULL

Because	NULL
ligation	NULL
of	NULL
the	NULL
Xhol/Sa/lI	NULL
sticky	NULL
ends	NULL
does	NULL
not	NULL
reform	NULL
these	NULL
restriction	NULL
enzyme	NULL
sites	NULL
,	NULL
the	NULL
multimerized	NULL
head-to-tail	NULL
fefO	NULL
elements	NULL
could	NULL
be	NULL
cloned	NULL
as	NULL
Xhol/Sall	NULL
fragments	NULL
in	NULL
pBluescript	NULL
II	NULL
SK	NULL
(	NULL
+	NULL
)	NULL
(	NULL
R.	NULL
Loew	NULL
,	NULL
personal	NULL
communication	NULL
)	NULL
.	NULL

We	NULL
used	NULL
standard	NULL
DNA	NULL
cloning	NULL
and	NULL
amplification	NULL
methods	NULL
(	NULL
41	NULL
)	NULL
,	NULL
and	NULL
all	NULL
mutations	NULL
were	NULL
verified	NULL
by	NULL
dideoxy	NULL
sequencing	NULL
using	NULL
ET	NULL
Dyeprimer	NULL
technology	NULL
(	NULL
Amersham	NULL
)	NULL
on	NULL
an	NULL
Applied	NULL
Biosystems	NULL
automated	NULL
DNA	NULL
sequencer	NULL
.	NULL

The	NULL
stepwise	NULL
cloning	NULL
procedure	NULL
was	NULL
as	NULL
follows	NULL
.	NULL

Cloning	NULL
.	NULL

(	NULL
i	NULL
)	NULL
Introduction	NULL
of	NULL
a	NULL
Sa/l	NULL
site	NULL
and	NULL
deletion	NULL
of	NULL
NF-	NULL
<	NULL
B	NULL
elements	NULL
in	NULL
the	NULL
HIV-1	NULL
LTR	NULL
promoter	NULL
.	NULL

To	NULL
facilitate	NULL
the	NULL
introduction	NULL
of	NULL
tefO	NULL
operator	NULL
elements	NULL
in	NULL
the	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
LTR	NULL
)	NULL
promoter	NULL
,	NULL
a	NULL
Sall	NULL
restriction	NULL
site	NULL
was	NULL
introduced	NULL
immediately	NULL
upstream	NULL
of	NULL
the	NULL
Sp1	NULL
sites	NULL
.	NULL

A	NULL
mutagenesis	NULL
PCR	NULL
(	NULL
42	NULL
)	NULL
was	NULL
done	NULL
on	NULL
pBlue3'LTR-luc	NULL
(	NULL
31	NULL
)	NULL
with	NULL
one	NULL
of	NULL
the	NULL
mutagenic	NULL
primers	NULL
(	NULL
xBSallSp1	NULL
or	NULL
SallSp1	NULL
[	NULL
primer	NULL
MJ	NULL
)	NULL
and	NULL
the	NULL
general	NULL
primers	NULL
M13reverse	NULL
(	NULL
primer	NULL
1	NULL
)	NULL
,	NULL
ExtN4Not	NULL
(	NULL
primer	NULL
2	NULL
)	NULL
,	NULL
and	NULL
Sp6anti-lue	NULL
(	NULL
primer	NULL
3	NULL
)	NULL
.	NULL

After	NULL
we	NULL
performed	NULL
separate	NULL
PCR	NULL
reactions	NULL
with	NULL
primer	NULL
sets	NULL
1+2	NULL
and	NULL
M+3	NULL
,	NULL
the	NULL
PCR	NULL
products	NULL
were	NULL
purified	NULL
from	NULL
a	NULL
gel	NULL
and	NULL
used	NULL
as	NULL
templates	NULL
in	NULL
a	NULL
final	NULL
PCR	NULL
with	NULL
primer	NULL
set	NULL
1+3	NULL
.	NULL

The	NULL
PCR	NULL
products	NULL
from	NULL
the	NULL
final	NULL
reactions	NULL
were	NULL
digested	NULL
with	NULL
Xhol	NULL
and	NULL
HindIII	NULL
and	NULL
used	NULL
to	NULL
replace	NULL
the	NULL
corresponding	NULL
fragments	NULL
in	NULL
the	NULL
pBlue3'LTR-luc	NULL
construct	NULL
,	NULL
thereby	NULL
generating	NULL
plasmids	NULL
pBlue3'LTR-lue-	NULL
Â«	NULL
kBSallSp1	NULL
(	NULL
K	NULL
promoter	NULL
)	NULL
and	NULL
pBlue3'LTR-lue-SallSp1	NULL
(	NULL
S	NULL
promoter	NULL
;	NULL
NF-xB	NULL
sequences	NULL
deleted	NULL
)	NULL
.	NULL

(	NULL
ii	NULL
)	NULL
Introduction	NULL
of	NULL
fefO	NULL
elements	NULL
in	NULL
the	NULL
HIV-1	NULL
LTR	NULL
promoter	NULL
.	NULL

The	NULL
pBlue3'LTR-luc-kBSallSp1	NULL
and	NULL
pBlue3'LTR-lue-SallSp1	NULL
constructs	NULL
were	NULL
linearized	NULL
by	NULL
Sall	NULL
digestion	NULL
.	NULL

The	NULL
2-mer	NULL
,	NULL
4-mer	NULL
,	NULL
and	NULL
6-mer	NULL
tefO	NULL
repeats	NULL
were	NULL
isolated	NULL
from	NULL
the	NULL
pBluescript	NULL
backbone	NULL
through	NULL
digestion	NULL
with	NULL
XhoI	NULL
and	NULL
SalI	NULL
and	NULL
then	NULL
ligated	NULL
into	NULL
the	NULL
linearized	NULL
luciferase	NULL
reporter	NULL
construct	NULL
.	NULL

Clones	NULL
were	NULL
selected	NULL
in	NULL
which	NULL
the	NULL
operator	NULL
sequences	NULL
are	NULL
present	NULL
in	NULL
the	NULL
sense	NULL
orientation	NULL
.	NULL

We	NULL
thus	NULL
generated	NULL
LTR	NULL
-luc	NULL
constructs	NULL
containing	NULL
2	NULL
,	NULL
4	NULL
,	NULL
and	NULL
6	NULL
tefO	NULL
element	NULL
repeats	NULL
placed	NULL
between	NULL
the	NULL
NF-kB	NULL
and	NULL
Sp1	NULL
binding	NULL
sites	NULL
(	NULL
xB-2xtetO-Sp1/	NULL
Â«	NULL
kB-4xtetO-Sp1/kB-6xtetO-Sp1	NULL
)	NULL
and	NULL
a	NULL
similar	NULL
set	NULL
of	NULL
reporter	NULL
constructs	NULL
in	NULL
which	NULL
both	NULL
NF-xB	NULL
elements	NULL
are	NULL
deleted	NULL
(	NULL
2xtetO-Sp1/4xtetO-Sp1/6xtetO-Sp1	NULL
)	NULL
.	NULL

Fortuitously	NULL
,	NULL
we	NULL
isolated	NULL
a	NULL
clone	NULL
in	NULL
which	NULL
two	NULL
tetrameric	NULL
fefO	NULL
repeats	NULL
were	NULL
ligated	NULL
in	NULL
tandem	NULL
,	NULL
yielding	NULL
a	NULL
promoter	NULL
with	NULL
eight	NULL
fefO	NULL
elements	NULL
between	NULL
the	NULL
NF-kB	NULL
and	NULL
Sp1	NULL
sites	NULL
(	NULL
B-8xtetO-Sp1	NULL
)	NULL
.	NULL

(	NULL
iii	NULL
)	NULL
Inactivation	NULL
of	NULL
the	NULL
TAR	NULL
RNA	NULL
element	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
TAR	NULL
bulge	NULL
and	NULL
loop	NULL
sequences	NULL
was	NULL
performed	NULL
in	NULL
a	NULL
PCR	NULL
on	NULL
the	NULL
pBlue3'LTR-lue	NULL
plasmid	NULL
(	NULL
31	NULL
)	NULL
with	NULL
the	NULL
primers	NULL
xBSallSp1	NULL
and	NULL
TARB123L13	NULL
.	NULL

The	NULL
PCR	NULL
product	NULL
was	NULL
cut	NULL
with	NULL
Sall	NULL
and	NULL
Sacl	NULL
and	NULL
exchanged	NULL
with	NULL
the	NULL
homologous	NULL
fragment	NULL
from	NULL
the	NULL
xB-SxtetO-Sp1	NULL
and	NULL
6xtetO-Sp1	NULL
LTR-luc	NULL
constructs	NULL
.	NULL

This	NULL
procedure	NULL
generated	NULL
plasmids	NULL
pBlue3'LTR-luc-kB-8xtetO-Sp1TAR*	NULL
(	NULL
pBlue3'LTR-lucK8TAR*	NULL
)	NULL
and	NULL
pBlue3'LTR-luc-6xtetO-Sp1TAR*	NULL
(	NULL
pBlue3'LTR-lucS6TAR*	NULL
)	NULL
.	NULL

(	NULL
iv	NULL
)	NULL
Construction	NULL
of	NULL
a	NULL
Nef-3'LTR	NULL
shuttle	NULL
vector	NULL
.	NULL

To	NULL
facilitate	NULL
the	NULL
modification	NULL
of	NULL
the	NULL
3	NULL
'	NULL
end	NULL
of	NULL
the	NULL
HIV-1	NULL
genome	NULL
,	NULL
we	NULL
constructed	NULL
a	NULL
shuttle	NULL
vector	NULL
to	NULL
exchange	NULL
Nef-3'LTR	NULL
sequences	NULL
with	NULL
the	NULL
full-length	NULL
HIV-1	NULL
infectious	NULL
clone	NULL
pLAI	NULL
(	NULL
43	NULL
)	NULL
.	NULL

To	NULL
this	NULL
end	NULL
,	NULL
pLAI	NULL
was	NULL
cut	NULL
with	NULL
BamHI	NULL
and	NULL
Bg/I	NULL
enzymes	NULL
,	NULL
and	NULL
the	NULL
resulting	NULL
2.3-kb	NULL
fragment	NULL
was	NULL
cloned	NULL
into	NULL
the	NULL
corresponding	NULL
sites	NULL
of	NULL
pBluescript	NULL
KS	NULL
(	NULL
+	NULL
)	NULL
,	NULL
generating	NULL
plasmid	NULL
pBlue3'LTRext	NULL
.	NULL

(	NULL
v	NULL
)	NULL
Deletion	NULL
of	NULL
U3	NULL
sequences	NULL
.	NULL

Mutagenesis	NULL
PCRs	NULL
(	NULL
42	NULL
)	NULL
were	NULL
performed	NULL
on	NULL
pBlue3'LTRext	NULL
with	NULL
mutagenic	NULL
primer	NULL
deltaU3	NULL
(	NULL
primer	NULL
M	NULL
)	NULL
and	NULL
general	NULL
primers	NULL
BgiIINef	NULL
(	NULL
primer	NULL
1	NULL
)	NULL
,	NULL
Sp6BspEI	NULL
(	NULL
primer	NULL
2	NULL
)	NULL
,	NULL
and	NULL
KB12-	NULL
(	NULL
primer	NULL
3	NULL
)	NULL
.	NULL

Separate	NULL
PCRs	NULL
were	NULL
performed	NULL
with	NULL
primer	NULL
sets	NULL
1+2	NULL
and	NULL
M+3	NULL
,	NULL
after	NULL
which	NULL
the	NULL
products	NULL
were	NULL
purified	NULL
from	NULL
a	NULL
gel	NULL
and	NULL
used	NULL
as	NULL
templates	NULL
in	NULL
a	NULL
final	NULL
PCR	NULL
with	NULL
primer	NULL
set	NULL
1+3	NULL
.	NULL

The	NULL
resulting	NULL
PCR	NULL
product	NULL
was	NULL
digested	NULL
with	NULL
Bg/II	NULL
and	NULL
BspEI	NULL
and	NULL
used	NULL
to	NULL
replace	NULL
the	NULL
corresponding	NULL
fragment	NULL
of	NULL
plasmid	NULL
pBlue3'LTRext	NULL
,	NULL
generating	NULL
pBlue3'LTRext-deltaU3	NULL
.	NULL

(	NULL
vi	NULL
)	NULL
Deletion	NULL
of	NULL
nef	NULL
sequences	NULL
and	NULL
introduction	NULL
of	NULL
an	NULL
XerI	NULL
site	NULL
.	NULL

A	NULL
mutagenesis	NULL
PCR	NULL
(	NULL
42	NULL
)	NULL
was	NULL
performed	NULL
on	NULL
pBlue3'LTRext-deltaU3	NULL
with	NULL
mutagenic	NULL
primer	NULL
XemlIdeltaNef	NULL
(	NULL
primer	NULL
M	NULL
)	NULL
and	NULL
general	NULL
primers	NULL
BamHIEny	NULL
(	NULL
primer	NULL
1	NULL
)	NULL
,	NULL
Smalanti-Nef	NULL
(	NULL
primer	NULL
2	NULL
)	NULL
,	NULL
and	NULL
Anti-U3att	NULL
(	NULL
primer	NULL
3	NULL
)	NULL
.	NULL

Separate	NULL
PCRs	NULL
were	NULL
performed	NULL
with	NULL
primer	NULL
sets	NULL
1+2	NULL
and	NULL
M+3	NULL
,	NULL
after	NULL
which	NULL
the	NULL
PCR	NULL
products	NULL
were	NULL
purified	NULL
from	NULL
a	NULL
gel	NULL
and	NULL
used	NULL
as	NULL
templates	NULL
in	NULL
a	NULL
final	NULL
PCR	NULL
with	NULL
primer	NULL
set	NULL
1+3	NULL
.	NULL

The	NULL
resulting	NULL
PCR	NULL
product	NULL
was	NULL
used	NULL
to	NULL
replace	NULL
wild-type	NULL
nef	NULL
sequences	NULL
in	NULL
the	NULL
pBlue3'LTRext-deltaU3	NULL
construct	NULL
through	NULL
the	NULL
Spel	NULL
(	NULL
vector-encoded	NULL
)	NULL
and	NULL
Bg/II	NULL
sites	NULL
,	NULL
generating	NULL
pBlue3'LTRext-deltaU3Xcml	NULL
.	NULL

(	NULL
vii	NULL
)	NULL
Insertion	NULL
of	NULL
the	NULL
rtTA	NULL
gene	NULL
in	NULL
the	NULL
nef	NULL
locus	NULL
.	NULL

The	NULL
plasmid	NULL
pUHD	NULL
52-1	NULL
,	NULL
containing	NULL
the	NULL
novel	NULL
rtTA-S2	NULL
gene	NULL
(	NULL
48	NULL
)	NULL
,	NULL
was	NULL
cut	NULL
with	NULL
XemI	NULL
and	NULL
BamHI	NULL
,	NULL
and	NULL
the	NULL
rtTA	NULL
gene	NULL
fragment	NULL
was	NULL
ligated	NULL
into	NULL
the	NULL
nef	NULL
locus	NULL
via	NULL
XemI	NULL
and	NULL
Bg/II	NULL
restriction	NULL
sites	NULL
in	NULL
pBlue3'LTRext-deltaU3XcmI	NULL
.	NULL

The	NULL
resulting	NULL
construct	NULL
was	NULL
named	NULL
pBlue3'LTRext-deltaU3rtTA	NULL
.	NULL

(	NULL
viii	NULL
)	NULL
Introduction	NULL
of	NULL
fefO	NULL
elements	NULL
and	NULL
TAR	NULL
mutations	NULL
in	NULL
the	NULL
5	NULL
'	NULL
and	NULL
3	NULL
'	NULL
LTR	NULL
shuttle	NULL
vectors	NULL
.	NULL

pBluc3'LTR-lucK8TAR*	NULL
and	NULL
pBlue3'LTR-lucS6TAR*	NULL
were	NULL
cut	NULL
with	NULL
BspEI	NULL
and	NULL
HindIII	NULL
and	NULL
used	NULL
to	NULL
replace	NULL
the	NULL
homologous	NULL
wild-type	NULL
fragments	NULL
J.	NULL
of	NULL
pBlueS'LTR	NULL
(	NULL
36	NULL
)	NULL
and	NULL
pBlue3'LTRext-deltaU3rtTA	NULL
.	NULL

Constructs	NULL
were	NULL
named	NULL
pBlue5'LTRK8TAR*/pBlue5'LTRS6TAR*	NULL
and	NULL
pBlue3'LTRext-deltaU3rtTA-K8TAR*/pBlue3'LTRext-deltaU3rtTA-S6TAR*	NULL
.	NULL

At	NULL
this	NULL
step	NULL
all	NULL
the	NULL
desired	NULL
modifications	NULL
have	NULL
been	NULL
introduced	NULL
in	NULL
the	NULL
5	NULL
'	NULL
and	NULL
3	NULL
'	NULL
LTR	NULL
shuttle	NULL
vectors	NULL
,	NULL
and	NULL
these	NULL
modified	NULL
LTRs	NULL
can	NULL
now	NULL
be	NULL
introduced	NULL
in	NULL
the	NULL
full-length	NULL
HIV-1	NULL
molecular	NULL
clone	NULL
pLAL	NULL
.	NULL

(	NULL
ix	NULL
)	NULL
Introduction	NULL
of	NULL
the	NULL
Tet	NULL
system	NULL
elements	NULL
in	NULL
the	NULL
5Â°	NULL
and	NULL
3	NULL
'	NULL
LTRs	NULL
of	NULL
pLAL	NULL
The	NULL
constructs	NULL
pBlueS'LTR-K8TAR*	NULL
and	NULL
pBlueS'LTR-S6TAR*	NULL
were	NULL
amplified	NULL
in	NULL
the	NULL
methylation-deficient	NULL
E.	NULL
coli	NULL
strain	NULL
3902	NULL
and	NULL
cut	NULL
with	NULL
Xbel	NULL
and	NULL
Clel	NULL
restriction	NULL
enzymes	NULL
.	NULL

Unmethylated	NULL
wild-type	NULL
pLAI	NULL
and	NULL
Tat	NULL
mutant	NULL
pLAI	NULL
Y26A	NULL
(	NULL
51	NULL
)	NULL
DNA	NULL
was	NULL
cut	NULL
with	NULL
these	NULL
two	NULL
enzymes	NULL
,	NULL
and	NULL
the	NULL
U3/R	NULL
region	NULL
of	NULL
the	NULL
5	NULL
'	NULL
LTR	NULL
of	NULL
these	NULL
constructs	NULL
was	NULL
replaced	NULL
by	NULL
the	NULL
K8TAR*	NULL
and	NULL
S6TAR*	NULL
fragments	NULL
,	NULL
yielding	NULL
constructs	NULL
KW	NULL
,	NULL
KY	NULL
,	NULL
SW	NULL
,	NULL
and	NULL
SY	NULL
(	NULL
``	NULL
K	NULL
``	NULL
and	NULL
``	NULL
S	NULL
``	NULL
denote	NULL
the	NULL
promoter	NULL
configuration	NULL
Â«	NULL
B-8xtetO-Sp1-TARB123L13	NULL
[	NULL
K	NULL
]	NULL
or	NULL
6xtetO-Sp1-TARB123L13	NULL
[	NULL
S	NULL
]	NULL
;	NULL
``	NULL
W	NULL
``	NULL
and	NULL
``	NULL
Y	NULL
``	NULL
indicate	NULL
the	NULL
status	NULL
of	NULL
the	NULL
Tat	NULL
gene	NULL
[	NULL
W	NULL
,	NULL
wild	NULL
type	NULL
;	NULL
Y	NULL
,	NULL
inactive	NULL
Y26A	NULL
Tat	NULL
mutant	NULL
]	NULL
)	NULL
.	NULL

The	NULL
rtTA	NULL
gene	NULL
and	NULL
fefO	NULL
elements	NULL
were	NULL
introduced	NULL
at	NULL
the	NULL
3	NULL
'	NULL
end	NULL
of	NULL
the	NULL
infectious	NULL
clones	NULL
by	NULL
cutting	NULL
the	NULL
KW	NULL
,	NULL
KY	NULL
,	NULL
SW	NULL
,	NULL
and	NULL
SY	NULL
constructs	NULL
with	NULL
BamHI	NULL
and	NULL
Bg/I	NULL
and	NULL
replacing	NULL
this	NULL
3	NULL
'	NULL
LTR	NULL
fragment	NULL
by	NULL
the	NULL
BamHI/Bg	NULL
!	NULL

I	NULL
fragments	NULL
of	NULL
the	NULL
pBlue3'LTRext-deltaU3rtTA-K8TAR	NULL
*/pBlue3'LTRext-deltaU3rtTA-S6TAR*	NULL
shuttle	NULL
vectors	NULL
,	NULL
such	NULL
that	NULL
identical	NULL
promoter	NULL
sequences	NULL
are	NULL
present	NULL
in	NULL
both	NULL
the	NULL
5	NULL
'	NULL
and	NULL
the	NULL
3	NULL
'	NULL
LTRs	NULL
(	NULL
constructs	NULL
KWK	NULL
,	NULL
KYK	NULL
,	NULL
SWS	NULL
,	NULL
and	NULL
SYS	NULL
)	NULL
.	NULL

Cells	NULL
and	NULL
viruses	NULL
.	NULL

The	NULL
SupT1	NULL
T-cell	NULL
line	NULL
was	NULL
grown	NULL
and	NULL
transfected	NULL
by	NULL
electroporation	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
3	NULL
)	NULL
.	NULL

Infection	NULL
of	NULL
SupT1	NULL
cells	NULL
with	NULL
the	NULL
SWS	NULL
virus	NULL
was	NULL
performed	NULL
by	NULL
incubating	NULL
6	NULL
X	NULL
10Â°	NULL
cells	NULL
with	NULL
2,200	NULL
ng	NULL
of	NULL
CA-p24	NULL
of	NULL
a	NULL
SupT1-produced	NULL
virus	NULL
stock	NULL
for	NULL
4	NULL
h	NULL
at	NULL
37Â°C	NULL
.	NULL

Subsequently	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
washed	NULL
twice	NULL
to	NULL
remove	NULL
residual	NULL
dox	NULL
that	NULL
was	NULL
present	NULL
in	NULL
the	NULL
virus	NULL
stock	NULL
and	NULL
split	NULL
into	NULL
six	NULL
different	NULL
culture	NULL
wells	NULL
,	NULL
after	NULL
which	NULL
each	NULL
culture	NULL
received	NULL
the	NULL
appropriate	NULL
addi-tives	NULL
.	NULL

In	NULL
some	NULL
cultures	NULL
,	NULL
dox	NULL
was	NULL
added	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
1,000	NULL
ng/ml	NULL
;	NULL
zidovudine	NULL
(	NULL
AZT	NULL
)	NULL
and	NULL
saquinavir	NULL
(	NULL
SQV	NULL
)	NULL
were	NULL
used	NULL
at	NULL
1,000	NULL
and	NULL
200	NULL
nM	NULL
,	NULL
re-spectively	NULL
.	NULL

The	NULL
culturing	NULL
and	NULL
transfection	NULL
by	NULL
CaPO	NULL
,	NULL
precipitation	NULL
of	NULL
the	NULL
adherent	NULL
C33A	NULL
cervical	NULL
carcinoma	NULL
cell	NULL
line	NULL
was	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBMCs	NULL
)	NULL
were	NULL
isolated	NULL
,	NULL
cultured	NULL
,	NULL
and	NULL
transfected	NULL
by	NULL
electroporation	NULL
as	NULL
described	NULL
earlier	NULL
(	NULL
3	NULL
)	NULL
.	NULL

At	NULL
7	NULL
days	NULL
after	NULL
transfection	NULL
,	NULL
half	NULL
of	NULL
the	NULL
culture	NULL
medium	NULL
was	NULL
replaced	NULL
by	NULL
medium	NULL
containing	NULL
2	NULL
x	NULL
10Â°	NULL
freshly	NULL
stimulated	NULL
PBMCs	NULL
.	NULL

Virus	NULL
production	NULL
in	NULL
the	NULL
culture	NULL
medium	NULL
was	NULL
quantitated	NULL
in	NULL
a	NULL
CA-p24	NULL
antigen	NULL
enzyme-linked	NULL
immunosorbent	NULL
assay	NULL
(	NULL
ELISA	NULL
)	NULL
.	NULL

RESULTS	NULL
Construction	NULL
of	NULL
HIV-rtTA	NULL
viruses	NULL
.	NULL

The	NULL
full-length	NULL
,	NULL
infectious	NULL
HIV-1	NULL
molecular	NULL
clone	NULL
pLAI	NULL
was	NULL
used	NULL
for	NULL
construction	NULL
of	NULL
an	NULL
HIV-rtTA	NULL
virus	NULL
genome	NULL
,	NULL
the	NULL
transcription	NULL
of	NULL
which	NULL
can	NULL
be	NULL
controlled	NULL
by	NULL
dox	NULL
.	NULL

The	NULL
viral	NULL
transcriptional	NULL
elements	NULL
TAR	NULL
and	NULL
Tat	NULL
(	NULL
marked	NULL
red	NULL
in	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
were	NULL
replaced	NULL
by	NULL
the	NULL
pro-karyotic	NULL
tetO-rtTA	NULL
elements	NULL
(	NULL
green	NULL
)	NULL
.	NULL

In	NULL
total	NULL
,	NULL
nine	NULL
cloning	NULL
steps	NULL
were	NULL
required	NULL
to	NULL
construct	NULL
these	NULL
putative	NULL
dox-dependent	NULL
viral	NULL
genomes	NULL
,	NULL
and	NULL
all	NULL
details	NULL
of	NULL
the	NULL
construction	NULL
are	NULL
provided	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

In	NULL
general	NULL
,	NULL
we	NULL
took	NULL
a	NULL
conservative	NULL
approach	NULL
with	NULL
regard	NULL
to	NULL
the	NULL
type	NULL
of	NULL
mutations	NULL
that	NULL
were	NULL
introduced	NULL
in	NULL
the	NULL
HIV-1	NULL
genome	NULL
in	NULL
order	NULL
to	NULL
minimize	NULL
the	NULL
chance	NULL
of	NULL
inactivating	NULL
important	NULL
sequences	NULL
that	NULL
constitute	NULL
replication	NULL
signals	NULL
.	NULL

TAR	NULL
and	NULL
Tat	NULL
inactivation	NULL
.	NULL

The	NULL
TAR	NULL
RNA	NULL
hairpin	NULL
motif	NULL
of	NULL
nascent	NULL
HIV-1	NULL
transcripts	NULL
is	NULL
recognized	NULL
by	NULL
the	NULL
viral	NULL
Tat	NULL
protein	NULL
and	NULL
the	NULL
cellular	NULL
cyclin	NULL
T	NULL
cofactor	NULL
(	NULL
19	NULL
,	NULL
53	NULL
)	NULL
.	NULL

Both	NULL
TAR	NULL
and	NULL
Tat	NULL
are	NULL
essential	NULL
for	NULL
transcription	NULL
from	NULL
the	NULL
viral	NULL
LTR	NULL
promoter	NULL
and	NULL
virus	NULL
replication	NULL
.	NULL

TAR	NULL
was	NULL
inactivated	NULL
by	NULL
mutation	NULL
of	NULL
multiple	NULL
nucleotides	NULL
in	NULL
the	NULL
single-stranded	NULL
bulge	NULL
and	NULL
loop	NULL
domains	NULL
,	NULL
the	NULL
binding	NULL
sites	NULL
for	NULL
Tat	NULL
and	NULL
cyclin	NULL
T	NULL
,	NULL
respectively	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

This	NULL
produces	NULL
a	NULL
fully	NULL
inactive	NULL
TAR	NULL
motif	NULL
because	NULL
even	NULL
single	NULL
point	NULL
mutations	NULL
in	NULL
one	NULL
of	NULL
these	NULL
single-stranded	NULL
TAR	NULL
domains	NULL
have	NULL
a	NULL
dramatic	NULL
effect	NULL
on	NULL
LTR	NULL
transcription	NULL
and	NULL
virus	NULL
replication	NULL
(	NULL
8	NULL
,	NULL
9	NULL
,	NULL
21	NULL
)	NULL
.	NULL

We	NULL
did	NULL
not	NULL
introduce	NULL
more	NULL
gross	NULL
sequence	NULL
changes	NULL
or	NULL
deletions	NULL
in	NULL
TAR	NULL
because	NULL
this	NULL
sequence	NULL
is	NULL
also	NULL
essential	NULL
for	NULL
virus	NULL
replication	NULL
as	NULL
a	NULL
repeat-R	NULL
region	NULL
during	NULL
strand	NULL
transfer	NULL
of	NULL
reverse	NULL
transcription	NULL
(	NULL
10	NULL
)	NULL
.	NULL

Although	NULL
we	NULL
demonstrated	NULL
previously	NULL
that	NULL
the	NULL
TAR	NULL
element	NULL
of	NULL
the	NULL
5	NULL
LTR	NULL
Vor	NULL
.	NULL

75	NULL
,	NULL
2001	NULL
A	NULL
tetO	NULL
TAR	NULL
insertion	NULL
-	NULL
mutation	NULL
HIV-1	NULL
m	NULL
_	NULL
rev	NULL
a_	NULL
CONDITIONAL	NULL
HIV-1	NULL
REPLICATION	NULL
_	NULL
981	NULL
o	NULL
HTA	NULL
_	NULL
tetO	NULL
__	NULL
TAR	NULL
*	NULL
insertion	NULL
insertion	NULL
mutation	NULL
/tat\	NULL
\	NULL
Â¢	NULL
/	NULL
-m	NULL
5	NULL
'	NULL
LTR	NULL
l	NULL
L	NULL
l	NULL
l	NULL
f	NULL
V	NULL
U	NULL
L_	NULL
_P	NULL
J	NULL
deletions	NULL
HIV-rtT	NULL
A	NULL
{	NULL
r	NULL
gag	NULL
a	NULL
16h	NULL
,	NULL
l	NULL
pol	NULL
|	NULL
vpr	NULL
|	NULL
|	NULL
Pk	NULL
vou	NULL
U	NULL
AJ	NULL
B	NULL
u	NULL
6G	NULL
c	NULL
C	NULL
L	NULL
tetO	NULL
oo	NULL
ng	NULL
A	NULL
,	NULL
<	NULL
<	NULL
-U	NULL
-	NULL
â	NULL
Egoigb	NULL
AAAAAAOOO	NULL
Ã©	NULL
OO0aAAAAAAAAOOO	NULL
=|	NULL
TAR	NULL
hairpin	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Design	NULL
of	NULL
dox-dependent	NULL
HIV-1	NULL
variants	NULL
.	NULL

(	NULL
A	NULL
)	NULL
HIV-1	NULL
genome	NULL
and	NULL
modifications	NULL
that	NULL
were	NULL
introduced	NULL
to	NULL
construct	NULL
HIV	NULL
-rtTA	NULL
.	NULL

Details	NULL
of	NULL
the	NULL
nine-step	NULL
construction	NULL
are	NULL
provided	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

In	NULL
brief	NULL
,	NULL
we	NULL
inactivated	NULL
the	NULL
TAR-Tat	NULL
transcriptional	NULL
axis	NULL
(	NULL
marked	NULL
in	NULL
red	NULL
)	NULL
,	NULL
which	NULL
was	NULL
replaced	NULL
by	NULL
the	NULL
tetracycline-inducible	NULL
rerO-rtTA	NULL
system	NULL
(	NULL
marked	NULL
in	NULL
green	NULL
)	NULL
.	NULL

Inactivation	NULL
of	NULL
TAR	NULL
and	NULL
Tat	NULL
is	NULL
indicated	NULL
by	NULL
crosses	NULL
through	NULL
the	NULL
motifs	NULL
.	NULL

The	NULL
size	NULL
of	NULL
the	NULL
HIV-rtTA	NULL
genome	NULL
is	NULL
larger	NULL
than	NULL
that	NULL
of	NULL
HIV-1	NULL
(	NULL
the	NULL
maps	NULL
are	NULL
not	NULL
drawn	NULL
to	NULL
scale	NULL
)	NULL
.	NULL

The	NULL
RNA	NULL
genome	NULL
of	NULL
HIV-1	NULL
LAI	NULL
is	NULL
9,229	NULL
nt	NULL
,	NULL
and	NULL
HIV-rtTA	NULL
is	NULL
either	NULL
9,767	NULL
nt	NULL
(	NULL
the	NULL
SYS	NULL
and	NULL
SWS	NULL
variants	NULL
)	NULL
or	NULL
9,875	NULL
nt	NULL
(	NULL
KYK	NULL
and	NULL
KWK	NULL
variants	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
TAR	NULL
hairpin	NULL
structure	NULL
and	NULL
inactivating	NULL
mutations	NULL
that	NULL
were	NULL
introduced	NULL
in	NULL
the	NULL
bulge	NULL
(	NULL
triple-nucleotide	NULL
substitution	NULL
)	NULL
and	NULL
in	NULL
the	NULL
loop	NULL
(	NULL
two	NULL
point	NULL
mutations	NULL
)	NULL
.	NULL

This	NULL
RNA	NULL
target	NULL
binds	NULL
the	NULL
Tat-cyclin	NULL
T1	NULL
complex	NULL
during	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
LTR	NULL
promoter	NULL
(	NULL
53	NULL
)	NULL
.	NULL

Panel	NULL
C	NULL
provides	NULL
some	NULL
details	NULL
of	NULL
the	NULL
fefO	NULL
insertion	NULL
in	NULL
the	NULL
LTR	NULL
promoter	NULL
.	NULL

The	NULL
U3	NULL
region	NULL
of	NULL
the	NULL
wild-type	NULL
LTR	NULL
(	NULL
left	NULL
)	NULL
encodes	NULL
two	NULL
NF-kB	NULL
sites	NULL
(	NULL
C	NULL
)	NULL
)	NULL
and	NULL
three	NULL
Sp1	NULL
sites	NULL
(	NULL
0	NULL
)	NULL
.	NULL

The	NULL
modified	NULL
LTR	NULL
(	NULL
right	NULL
)	NULL
contains	NULL
either	NULL
six	NULL
or	NULL
eight	NULL
refO	NULL
operators	NULL
(	NULL
&	NULL
)	NULL
upstream	NULL
of	NULL
the	NULL
Sp1	NULL
sites	NULL
.	NULL

The	NULL
six	NULL
refO	NULL
variant	NULL
(	NULL
mutant	NULL
S	NULL
)	NULL
has	NULL
no	NULL
sites	NULL
,	NULL
whereas	NULL
both	NULL
NF-kB	NULL
sites	NULL
are	NULL
present	NULL
upstream	NULL
of	NULL
the	NULL
eight	NULL
rerO	NULL
operators	NULL
(	NULL
mutant	NULL
K	NULL
)	NULL
.	NULL

The	NULL
arrow	NULL
marks	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
at	NULL
the	NULL
U3-R	NULL
border	NULL
,	NULL
which	NULL
also	NULL
denotes	NULL
the	NULL
5	NULL
'	NULL
border	NULL
of	NULL
the	NULL
TAR	NULL
RNA	NULL
hairpin	NULL
motif	NULL
.	NULL

is	NULL
inherited	NULL
in	NULL
both	NULL
LTRs	NULL
of	NULL
the	NULL
viral	NULL
progeny	NULL
(	NULL
38	NULL
)	NULL
,	NULL
the	NULL
inactive	NULL
TAR	NULL
motif	NULL
was	NULL
inserted	NULL
in	NULL
both	NULL
LTRs	NULL
to	NULL
minimize	NULL
the	NULL
chance	NULL
of	NULL
reversion	NULL
to	NULL
the	NULL
wild-type	NULL
virus	NULL
by	NULL
a	NULL
recombination	NULL
event	NULL
.	NULL

Inactivation	NULL
of	NULL
the	NULL
Tat	NULL
protein	NULL
was	NULL
accomplished	NULL
by	NULL
introduction	NULL
of	NULL
the	NULL
Tyr26Ala	NULL
point	NULL
mutation	NULL
.	NULL

This	NULL
single	NULL
amino	NULL
acid	NULL
change	NULL
results	NULL
in	NULL
a	NULL
severe	NULL
loss	NULL
of	NULL
Tat	NULL
transcriptional	NULL
activity	NULL
and	NULL
virus	NULL
replication	NULL
(	NULL
51	NULL
)	NULL
.	NULL

The	NULL
corresponding	NULL
codon	NULL
change	NULL
(	NULL
UAU	NULL
to	NULL
GCC	NULL
)	NULL
was	NULL
designed	NULL
to	NULL
restrict	NULL
the	NULL
likelihood	NULL
of	NULL
simple	NULL
reversion	NULL
to	NULL
the	NULL
wild-type	NULL
amino	NULL
acid	NULL
,	NULL
which	NULL
requires	NULL
at	NULL
least	NULL
two	NULL
nucleotide	NULL
substitutions	NULL
(	NULL
50	NULL
)	NULL
.	NULL

It	NULL
has	NULL
been	NULL
suggested	NULL
that	NULL
Tat	NULL
may	NULL
play	NULL
additional	NULL
roles	NULL
in	NULL
the	NULL
replication	NULL
cycle	NULL
besides	NULL
its	NULL
transcriptional	NULL
function	NULL
(	NULL
26	NULL
,	NULL
28	NULL
,	NULL
47	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
Tat	NULL
may	NULL
facilitate	NULL
HIV-rtTA	NULL
replication	NULL
even	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
an	NULL
intact	NULL
TAR	NULL
element	NULL
,	NULL
and	NULL
we	NULL
therefore	NULL
also	NULL
constructed	NULL
viruses	NULL
that	NULL
retained	NULL
the	NULL
wild-type	NULL
fat	NULL
gene	NULL
.	NULL

These	NULL
constructs	NULL
are	NULL
referred	NULL
to	NULL
here	NULL
as	NULL
Y	NULL
(	NULL
tyrosine	NULL
mutant	NULL
)	NULL
and	NULL
W	NULL
(	NULL
wild-type	NULL
)	NULL
.	NULL

rtTA	NULL
and	NULL
fefO	NULL
insertion	NULL
.	NULL

Two	NULL
deletions	NULL
were	NULL
introduced	NULL
in	NULL
the	NULL
3'-terminal	NULL
nef	NULL
gene	NULL
of	NULL
the	NULL
HIV-1	NULL
genome	NULL
to	NULL
create	NULL
space	NULL
for	NULL
insertion	NULL
of	NULL
the	NULL
components	NULL
of	NULL
the	NULL
Tet	NULL
system	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

We	NULL
removed	NULL
a	NULL
250-nucleotide	NULL
(	NULL
nt	NULL
)	NULL
upstream	NULL
nef	NULL
fragment	NULL
and	NULL
a	NULL
200-nt	NULL
downstream	NULL
fragment	NULL
overlapping	NULL
the	NULL
U3	NULL
region	NULL
of	NULL
the	NULL
3	NULL
'	NULL
LTR	NULL
.	NULL

This	NULL
U3	NULL
deletion	NULL
will	NULL
be	NULL
inherited	NULL
by	NULL
the	NULL
viral	NULL
progeny	NULL
in	NULL
both	NULL
LTRs	NULL
.	NULL

The	NULL
exact	NULL
borders	NULL
of	NULL
the	NULL
nef	NULL
and	NULL
U3	NULL
deletions	NULL
were	NULL
carefully	NULL
chosen	NULL
such	NULL
that	NULL
important	NULL
cis-acting	NULL
sequences	NULL
for	NULL
virus	NULL
replication	NULL
were	NULL
not	NULL
affected	NULL
.	NULL

In	NULL
particular	NULL
,	NULL
we	NULL
maintained	NULL
approximately	NULL
80	NULL
nt	NULL
around	NULL
the	NULL
5	NULL
'	NULL
end	NULL
of	NULL
the	NULL
3	NULL
'	NULL
LTR	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

This	NULL
region	NULL
encodes	NULL
multiple	NULL
sequence	NULL
elements	NULL
that	NULL
are	NULL
critical	NULL
for	NULL
reverse	NULL
transcription	NULL
(	NULL
30	NULL
)	NULL
and	NULL
integration	NULL
(	NULL
12	NULL
)	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
we	NULL
tried	NULL
to	NULL
mimic	NULL
spontaneous	NULL
deletions	NULL
that	NULL
have	NULL
been	NULL
observed	NULL
in	NULL
the	NULL
nef-U3	NULL
region	NULL
of	NULL
several	NULL
HIV	NULL
and	NULL
SIV	NULL
variants	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
replication	NULL
studies	NULL
(	NULL
22	NULL
,	NULL
29	NULL
,	NULL
33	NULL
,	NULL
34	NULL
)	NULL
.	NULL

To	NULL
prepare	NULL
for	NULL
the	NULL
insertion	NULL
of	NULL
the	NULL
exogenous	NULL
rtTA	NULL
gene	NULL
982	NULL
VERHOEF	NULL
ET	NULL
AL	NULL
.	NULL

TABLE	NULL
1	NULL
.	NULL

HIV-rtTA	NULL
constructs	NULL
HIV-rtTA	NULL
Promoter	NULL
tat	NULL
gene	NULL
TAR	NULL
variant	NULL
configuration	NULL
``	NULL
type	NULL
type	NULL
KWK	NULL
Wild	NULL
type	NULL
Mutant	NULL
KYK	NULL
Mutant	NULL
Mutant	NULL
SWS	NULL
AAAAAAOOO	NULL
Wild	NULL
type	NULL
Mutant	NULL
SYS	NULL
AAAAAAOOO	NULL
Mutant	NULL
Mutant	NULL
``	NULL
C	NULL
,	NULL
NF-xB	NULL
;	NULL
A	NULL
,	NULL
refO	NULL
;	NULL
O	NULL
,	NULL
Sp1	NULL
.	NULL

into	NULL
the	NULL
position	NULL
of	NULL
the	NULL
nef	NULL
gene	NULL
,	NULL
a	NULL
short	NULL
synthetic	NULL
sequence	NULL
was	NULL
inserted	NULL
that	NULL
provides	NULL
a	NULL
translational	NULL
start	NULL
codon	NULL
(	NULL
underlined	NULL
)	NULL
in	NULL
an	NULL
optimized	NULL
sequence	NULL
context	NULL
(	NULL
CCAUGU	NULL
[	NULL
39	NULL
]	NULL
)	NULL
and	NULL
convenient	NULL
restriction	NULL
enzyme	NULL
recognition	NULL
sites	NULL
.	NULL

We	NULL
used	NULL
the	NULL
novel	NULL
rtTA-S2	NULL
variant	NULL
with	NULL
improved	NULL
properties	NULL
for	NULL
insertion	NULL
in	NULL
frame	NULL
with	NULL
the	NULL
optimized	NULL
start	NULL
codon	NULL
(	NULL
48	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
rtTA	NULL
translation	NULL
should	NULL
occur	NULL
from	NULL
the	NULL
subgenomic	NULL
mRNA	NULL
that	NULL
was	NULL
originally	NULL
meant	NULL
for	NULL
expression	NULL
of	NULL
the	NULL
Nef	NULL
protein	NULL
.	NULL

To	NULL
identify	NULL
the	NULL
optimal	NULL
configuration	NULL
of	NULL
an	NULL
LTR	NULL
promoter	NULL
with	NULL
rtTA-responsive	NULL
fefO	NULL
elements	NULL
,	NULL
we	NULL
performed	NULL
transient	NULL
transfection	NULL
studies	NULL
with	NULL
a	NULL
variety	NULL
of	NULL
LTR-luc	NULL
constructs	NULL
(	NULL
K.	NULL
Verhoef	NULL
et	NULL
al	NULL
.	NULL

,	NULL
manuscript	NULL
in	NULL
preparation	NULL
)	NULL
.	NULL

We	NULL
varied	NULL
the	NULL
number	NULL
of	NULL
tetO	NULL
motifs	NULL
(	NULL
2	NULL
,	NULL
4	NULL
,	NULL
6	NULL
,	NULL
or	NULL
8	NULL
)	NULL
that	NULL
were	NULL
inserted	NULL
upstream	NULL
of	NULL
the	NULL
three	NULL
Sp1	NULL
binding	NULL
sites	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
)	NULL
.	NULL

We	NULL
also	NULL
tested	NULL
constructs	NULL
with	NULL
or	NULL
without	NULL
the	NULL
two	NULL
upstream	NULL
NF-	NULL
Â«	NULL
kB	NULL
elements	NULL
.	NULL

The	NULL
two	NULL
promoters	NULL
that	NULL
provided	NULL
most	NULL
robust	NULL
dox-inducible	NULL
transcriptional	NULL
activation	NULL
were	NULL
selected	NULL
for	NULL
insertion	NULL
into	NULL
the	NULL
HIV-1	NULL
genome	NULL
,	NULL
and	NULL
these	NULL
LTRs	NULL
are	NULL
schematically	NULL
depicted	NULL
in	NULL
Fig	NULL
.	NULL

1C	NULL
.	NULL

They	NULL
will	NULL
be	NULL
referred	NULL
to	NULL
as	NULL
the	NULL
K	NULL
mutant	NULL
(	NULL
2	NULL
NF-kB	NULL
+	NULL
8	NULL
tetO	NULL
+3	NULL
Sp1	NULL
sites	NULL
)	NULL
and	NULL
the	NULL
S	NULL
mutant	NULL
(	NULL
6	NULL
tetO	NULL
+3	NULL
Sp1	NULL
sites	NULL
)	NULL
.	NULL

Although	NULL
insertion	NULL
into	NULL
the	NULL
U3	NULL
region	NULL
of	NULL
the	NULL
3	NULL
'	NULL
LTR	NULL
will	NULL
be	NULL
sufficient	NULL
to	NULL
produce	NULL
a	NULL
mutant	NULL
10000000	NULL
1000000	NULL
|	NULL
AWK	NULL
100000	NULL
7-~	NULL
=	NULL
10000	NULL
B	NULL
)	NULL
1000	NULL
8	NULL
100	NULL
xe	NULL
x	NULL
x	NULL
o	NULL
2	NULL
4	NULL
6	NULL
8	NULL
<	NULL
F	NULL
COU	NULL
Â©	NULL
10000000	NULL
7	NULL
<	NULL
T	NULL
1000000	NULL
|	NULL
SwsS	NULL
o	NULL
100000	NULL
10000	NULL
{	NULL
1000	NULL
100	NULL
xe	NULL
x	NULL
x	NULL
o	NULL
2	NULL
4	NULL
6	NULL
8	NULL
J.	NULL
ViroL	NULL
.	NULL

progeny	NULL
,	NULL
we	NULL
also	NULL
introduced	NULL
the	NULL
fetO	NULL
motifs	NULL
in	NULL
the	NULL
5	NULL
'	NULL
LTR	NULL
to	NULL
generate	NULL
molecular	NULL
clones	NULL
of	NULL
which	NULL
the	NULL
initial	NULL
round	NULL
of	NULL
gene	NULL
expression	NULL
in	NULL
transfected	NULL
cells	NULL
is	NULL
also	NULL
dox	NULL
dependent	NULL
.	NULL

Thus	NULL
,	NULL
both	NULL
LTRs	NULL
were	NULL
modified	NULL
,	NULL
and	NULL
this	NULL
was	NULL
done	NULL
in	NULL
the	NULL
wild-type	NULL
(	NULL
W	NULL
)	NULL
and	NULL
mutant	NULL
(	NULL
Y	NULL
)	NULL
Tat	NULL
backgrounds	NULL
,	NULL
resulting	NULL
in	NULL
four	NULL
HIV-rtTA	NULL
constructs	NULL
:	NULL
KWK	NULL
,	NULL
KYK	NULL
,	NULL
SWS	NULL
,	NULL
and	NULL
SYS	NULL
.	NULL

All	NULL
HIV-rtTA	NULL
molecular	NULL
clones	NULL
have	NULL
the	NULL
TAR	NULL
inactivation	NULL
and	NULL
rtTA	NULL
insertion	NULL
in	NULL
common	NULL
,	NULL
but	NULL
they	NULL
differ	NULL
in	NULL
the	NULL
status	NULL
of	NULL
the	NULL
tat	NULL
gene	NULL
and	NULL
the	NULL
type	NULL
of	NULL
fetO	NULL
insert	NULL
(	NULL
summarized	NULL
in	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

The	NULL
virus	NULL
variant	NULL
KWXK	NULL
is	NULL
most	NULL
wild	NULL
type-like	NULL
because	NULL
it	NULL
maintained	NULL
the	NULL
NF-B	NULL
sites	NULL
and	NULL
a	NULL
wild-type	NULL
Tat	NULL
protein	NULL
,	NULL
and	NULL
SYS	NULL
is	NULL
the	NULL
most	NULL
minimal	NULL
HIV-rtTA	NULL
version	NULL
.	NULL

HIV-rtTA	NULL
replicates	NULL
in	NULL
a	NULL
dox-dependent	NULL
manner	NULL
.	NULL

The	NULL
four	NULL
pLAI	NULL
plasmids	NULL
were	NULL
individually	NULL
transfected	NULL
into	NULL
the	NULL
SupT1	NULL
T-cell	NULL
line	NULL
to	NULL
test	NULL
for	NULL
their	NULL
replication	NULL
capacity	NULL
.	NULL

The	NULL
culture	NULL
was	NULL
maintained	NULL
at	NULL
various	NULL
dox	NULL
levels	NULL
,	NULL
and	NULL
virus	NULL
replication	NULL
was	NULL
monitored	NULL
by	NULL
measuring	NULL
the	NULL
amount	NULL
of	NULL
CA-p24	NULL
produced	NULL
in	NULL
the	NULL
culture	NULL
medium	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

In	NULL
the	NULL
presence	NULL
of	NULL
optimal	NULL
dox	NULL
levels	NULL
(	NULL
1,000	NULL
ng/m	NULL
!	NULL
)	NULL

,	NULL
we	NULL
measured	NULL
profound	NULL
replication	NULL
of	NULL
all	NULL
four	NULL
HIV-rtTA	NULL
viruses	NULL
.	NULL

No	NULL
virus	NULL
replication	NULL
was	NULL
observed	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
dox	NULL
,	NULL
indicating	NULL
that	NULL
replication	NULL
is	NULL
strictly	NULL
dependent	NULL
on	NULL
the	NULL
inserted	NULL
Tet	NULL
system	NULL
.	NULL

The	NULL
Tet	NULL
system	NULL
is	NULL
ideally	NULL
suited	NULL
to	NULL
modulate	NULL
the	NULL
level	NULL
of	NULL
transcriptional	NULL
activation	NULL
in	NULL
a	NULL
stepwise	NULL
manner	NULL
by	NULL
changing	NULL
the	NULL
amount	NULL
of	NULL
dox	NULL
(	NULL
4	NULL
)	NULL
.	NULL

Indeed	NULL
,	NULL
replication	NULL
of	NULL
the	NULL
HIV-rtTA	NULL
viruses	NULL
can	NULL
also	NULL
be	NULL
modulated	NULL
at	NULL
suboptimal	NULL
concentrations	NULL
of	NULL
the	NULL
inducing	NULL
dox	NULL
reagent	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

A	NULL
progressive	NULL
reduction	NULL
in	NULL
replication	NULL
rates	NULL
of	NULL
all	NULL
four	NULL
rtTA-viruses	NULL
was	NULL
observed	NULL
at	NULL
300	NULL
and	NULL
100	NULL
ng	NULL
of	NULL
dox	NULL
per	NULL
ml	NULL
,	NULL
and	NULL
virus	NULL
replication	NULL
was	NULL
nearly	NULL
abolished	NULL
at	NULL
30	NULL
ng/ml	NULL
.	NULL

The	NULL
SupT1	NULL
cells	NULL
were	NULL
killed	NULL
within	NULL
1	NULL
week	NULL
by	NULL
massive	NULL
virus-induced	NULL
syncytia	NULL
,	NULL
and	NULL
the	NULL
peak	NULL
CA-p24	NULL
production	NULL
is	NULL
similar	NULL
to	NULL
what	NULL
we	NULL
regularly	NULL
observe	NULL
in	NULL
infections	NULL
with	NULL
the	NULL
wild-type	NULL
LAI	NULL
10000000	NULL
1000000	NULL
{	NULL
KYK	NULL
100000	NULL
10000	NULL
1	NULL
1000	NULL
-	NULL
dox	NULL
``	NULL
a	NULL
a	NULL
``	NULL
a	NULL
,	NULL
.	NULL

~	NULL
,	NULL
_	NULL
(	NULL
Nym	NULL
|	NULL
-x-0Q	NULL
10000000	NULL
'	NULL
--	NULL
30	NULL
1000000	NULL
-	NULL
SYS	NULL
â	NULL
Il	NULL
â	NULL
gg	NULL
100000	NULL
[	NULL
rï¬g	NULL
10000	NULL
{	NULL
1000	NULL
{	NULL
100	NULL
x	NULL
x	NULL
x	NULL
0	NULL
2	NULL
4	NULL
6	NULL
8	NULL
days	NULL
post	NULL
transfection	NULL
FIG	NULL
.	NULL

2.	NULL
dox-controlled	NULL
replication	NULL
of	NULL
the	NULL
HIV-rtTA	NULL
viruses	NULL
.	NULL

The	NULL
SupT1	NULL
T-cell	NULL
line	NULL
was	NULL
electroporated	NULL
with	NULL
10	NULL
pg	NULL
of	NULL
the	NULL
indicated	NULL
molecular	NULL
clones	NULL
,	NULL
and	NULL
cells	NULL
were	NULL
cultured	NULL
without	NULL
or	NULL
with	NULL
an	NULL
increasing	NULL
concentration	NULL
of	NULL
dox	NULL
(	NULL
0	NULL
to	NULL
1,000	NULL
ng/ml	NULL
)	NULL
.	NULL

Some	NULL
of	NULL
the	NULL
cultures	NULL
were	NULL
stopped	NULL
at	NULL
day	NULL
5	NULL
because	NULL
of	NULL
massive	NULL
HIV-induced	NULL
syncytium	NULL
formation	NULL
and	NULL
cell	NULL
death	NULL
.	NULL

Virus	NULL
production	NULL
was	NULL
measured	NULL
by	NULL
CA-p24	NULL
ELISA	NULL
on	NULL
culture	NULL
supernatant	NULL
samples	NULL
.	NULL

vor	NULL
.	NULL

75	NULL
,	NULL
2001	NULL
100000	NULL
10000	NULL
{	NULL
1000	NULL
CA-p24	NULL
(	NULL
pg/ml	NULL
!	NULL
)	NULL

100	NULL
0	NULL
5	NULL
10	NULL
15	NULL
days	NULL
post	NULL
transfection	NULL
FIG	NULL
.	NULL

3.	NULL
dox-dependent	NULL
replication	NULL
of	NULL
HIV-rtTA	NULL
viruses	NULL
in	NULL
primary	NULL
cells	NULL
.	NULL

PBMCs	NULL
were	NULL
electroporated	NULL
with	NULL
the	NULL
KWK	NULL
(	NULL
diamonds	NULL
)	NULL
and	NULL
KYK	NULL
(	NULL
triangles	NULL
)	NULL
constructs	NULL
(	NULL
20	NULL
g	NULL
)	NULL
,	NULL
and	NULL
the	NULL
cultures	NULL
were	NULL
maintained	NULL
without	NULL
(	NULL
open	NULL
symbols	NULL
)	NULL
or	NULL
with	NULL
(	NULL
1,000	NULL
ng/ml	NULL
!	NULL
)	NULL

(	NULL
solid	NULL
symbols	NULL
)	NULL
dox	NULL
.	NULL

Fresh	NULL
uninfected	NULL
cells	NULL
were	NULL
added	NULL
immediately	NULL
after	NULL
transfection	NULL
and	NULL
at	NULL
day	NULL
6	NULL
postinfection	NULL
.	NULL

Virus	NULL
production	NULL
was	NULL
measured	NULL
by	NULL
CA-p24	NULL
ELISA	NULL
on	NULL
culture	NULL
supernatant	NULL
samples	NULL
.	NULL

virus	NULL
.	NULL

Nevertheless	NULL
,	NULL
the	NULL
HIV-rtTA	NULL
variants	NULL
have	NULL
significantly	NULL
reduced	NULL
replication	NULL
capacity	NULL
compared	NULL
to	NULL
wild-type	NULL
HIV-1	NULL
(	NULL
re-sults	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

We	NULL
managed	NULL
to	NULL
passage	NULL
all	NULL
four	NULL
HIV-rtTA	NULL
viruses	NULL
as	NULL
cell-free	NULL
inocula	NULL
onto	NULL
fresh	NULL
,	NULL
uninfected	NULL
T	NULL
cells	NULL
,	NULL
and	NULL
a	NULL
spreading	NULL
infection	NULL
was	NULL
sustained	NULL
for	NULL
at	NULL
least	NULL
5	NULL
weeks	NULL
(	NULL
five	NULL
passages	NULL
)	NULL
.	NULL

The	NULL
combined	NULL
results	NULL
of	NULL
several	NULL
independent	NULL
replication	NULL
assays	NULL
,	NULL
either	NULL
started	NULL
by	NULL
transfection	NULL
or	NULL
infection	NULL
,	NULL
indi-	NULL
CONDITIONAL	NULL
HIV-1	NULL
REPLICATION	NULL
_	NULL
983	NULL
cated	NULL
that	NULL
there	NULL
are	NULL
modest	NULL
but	NULL
reproducible	NULL
differences	NULL
in	NULL
the	NULL
replication	NULL
efficiency	NULL
of	NULL
the	NULL
four	NULL
HIV-rtTA	NULL
constructs	NULL
.	NULL

The	NULL
most	NULL
efficient	NULL
replication	NULL
was	NULL
measured	NULL
for	NULL
the	NULL
KWK	NULL
variant	NULL
that	NULL
maintained	NULL
both	NULL
the	NULL
NF-KB	NULL
sites	NULL
and	NULL
a	NULL
functional	NULL
tat	NULL
gene	NULL
,	NULL
but	NULL
the	NULL
other	NULL
variants	NULL
were	NULL
not	NULL
much	NULL
delayed	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
the	NULL
minimal	NULL
SYS	NULL
virus	NULL
replicated	NULL
most	NULL
weakly	NULL
,	NULL
but	NULL
this	NULL
variant	NULL
also	NULL
induced	NULL
a	NULL
spreading	NULL
infection	NULL
.	NULL

From	NULL
these	NULL
experiments	NULL
the	NULL
following	NULL
ranking	NULL
order	NULL
of	NULL
replication	NULL
was	NULL
apparent	NULL
:	NULL
LAI	NULL
(	NULL
wild	NULL
type	NULL
)	NULL
>	NULL
KWK	NULL
>	NULL
KYK	NULL
,	NULL
SWS	NULL
>	NULL
SYS	NULL
.	NULL

Putative	NULL
HIV-rtTA	NULL
vaccine	NULL
viruses	NULL
should	NULL
be	NULL
able	NULL
to	NULL
replicate	NULL
in	NULL
primary	NULL
cells	NULL
.	NULL

The	NULL
LAI	NULL
molecular	NULL
clone	NULL
used	NULL
in	NULL
these	NULL
studies	NULL
represents	NULL
a	NULL
primary	NULL
isolate	NULL
that	NULL
is	NULL
able	NULL
to	NULL
efficiently	NULL
infect	NULL
primary	NULL
cells	NULL
(	NULL
43	NULL
,	NULL
52	NULL
)	NULL
,	NULL
but	NULL
a	NULL
complication	NULL
of	NULL
our	NULL
design	NULL
is	NULL
that	NULL
we	NULL
removed	NULL
the	NULL
nef	NULL
gene	NULL
that	NULL
contributes	NULL
to	NULL
optimal	NULL
virus	NULL
replication	NULL
in	NULL
primary	NULL
cells	NULL
(	NULL
18	NULL
)	NULL
.	NULL

We	NULL
transfected	NULL
pooled	NULL
PBMCs	NULL
by	NULL
means	NULL
of	NULL
electroporation	NULL
with	NULL
the	NULL
KWK	NULL
and	NULL
KYK	NULL
molecular	NULL
clones	NULL
and	NULL
measured	NULL
CA-p24	NULL
production	NULL
in	NULL
the	NULL
culture	NULL
supernatant	NULL
for	NULL
up	NULL
to	NULL
2	NULL
weeks	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Both	NULL
HIV-rtTA	NULL
variants	NULL
,	NULL
with	NULL
or	NULL
without	NULL
a	NULL
functional	NULL
tat	NULL
gene	NULL
,	NULL
replicated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1,000	NULL
ng	NULL
of	NULL
dox	NULL
per	NULL
ml	NULL
,	NULL
whereas	NULL
no	NULL
replication	NULL
was	NULL
detectable	NULL
without	NULL
dox	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
that	NULL
the	NULL
HIV-rtTA	NULL
viruses	NULL
can	NULL
replicate	NULL
in	NULL
primary	NULL
cells	NULL
,	NULL
despite	NULL
the	NULL
absence	NULL
of	NULL
the	NULL
nef	NULL
function	NULL
.	NULL

Turning	NULL
virus	NULL
replication	NULL
on	NULL
and	NULL
off	NULL
in	NULL
a	NULL
reversible	NULL
manner	NULL
.	NULL

Subsequent	NULL
tests	NULL
were	NULL
performed	NULL
with	NULL
the	NULL
SWS	NULL
virus	NULL
in	NULL
SupT1	NULL
infections	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

First	NULL
,	NULL
we	NULL
repeated	NULL
the	NULL
dox	NULL
response	NULL
exper-iment	NULL
.	NULL

Efficient	NULL
virus	NULL
replication	NULL
was	NULL
observed	NULL
at	NULL
1,000	NULL
ng	NULL
of	NULL
dox	NULL
per	NULL
ml	NULL
,	NULL
but	NULL
100	NULL
ng	NULL
of	NULL
dox	NULL
per	NULL
ml	NULL
was	NULL
not	NULL
sufficient	NULL
to	NULL
support	NULL
a	NULL
spreading	NULL
infection	NULL
in	NULL
this	NULL
more	NULL
sensitive	NULL
replication	NULL
10000000	NULL
-	NULL
10000000	NULL
1000000	NULL
|	NULL
A	NULL
1000000	NULL
|	NULL
B	NULL
e	NULL
100000	NULL
-e-	NULL
-	NULL
dox	NULL
100000	NULL
--	NULL
-	NULL
dox	NULL
+	NULL
10000	NULL
--	NULL
+	NULL
dox	NULL
(	NULL
100	NULL
)	NULL
|	NULL
10000	NULL
-s-+	NULL
dox	NULL
(	NULL
day	NULL
0	NULL
)	NULL
i	NULL
dox	NULL
(	NULL
1000	NULL
)	NULL
-o-+	NULL
dox	NULL
(	NULL
day	NULL
3	NULL
)	NULL
3	NULL
1000	NULL
1000	NULL
-2-	NULL
+	NULL
GOxt	NULL
cay	NULL
&	NULL
100	NULL
-	NULL
100	NULL
_-_	NULL
,	NULL
Fea	NULL
0	NULL
0	NULL
5	NULL
0	NULL
100	NULL
as	NULL
0	NULL
0	NULL
Â§	NULL
100	NULL
45	NULL
CL	NULL
Ne	NULL
``	NULL
v	NULL
CO	NULL
Â©	NULL
1000000	NULL
10000000	NULL
<	NULL
100000	NULL
1000000	NULL
|	NULL
D	NULL
ee	NULL
O	NULL
â	NULL
â	NULL
-s-+	NULL
dox	NULL
-=-	NULL
+	NULL
dox	NULL
100000	NULL
10000	NULL
-o-	NULL
-	NULL
dox	NULL
(	NULL
day	NULL
3	NULL
)	NULL
|	NULL
10000	NULL
-o-	NULL
+	NULL
dox	NULL
+	NULL
SQV	NULL
:	NULL
-	NULL
dOx	NULL
(	NULL
da	NULL
h	NULL
ây	NULL
)	NULL
J	NULL
!	NULL

-s-+	NULL
dox	NULL
+	NULL
AZT	NULL
|	NULL
1000	NULL
1000	NULL
-	NULL
@	NULL
-+dox	NULL
+	NULL
AZT	NULL
|	NULL
100	NULL
100	NULL
0	NULL
0	NULL
5	NULL
0	NULL
100	NULL
45	NULL
days	NULL
post	NULL
infection	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Replication	NULL
of	NULL
HIV-rtTA	NULL
can	NULL
be	NULL
turned	NULL
on	NULL
and	NULL
turned	NULL
off	NULL
.	NULL

These	NULL
experiments	NULL
were	NULL
performed	NULL
with	NULL
the	NULL
SWS	NULL
virus	NULL
,	NULL
but	NULL
similar	NULL
experiments	NULL
have	NULL
been	NULL
performed	NULL
with	NULL
the	NULL
other	NULL
HIV-rtTA	NULL
variants	NULL
.	NULL

We	NULL
used	NULL
the	NULL
SWS	NULL
virus	NULL
(	NULL
2,200	NULL
ng	NULL
of	NULL
CA-p24	NULL
)	NULL
to	NULL
infect	NULL
6	NULL
x	NULL
10Â°	NULL
SupT1	NULL
cells	NULL
at	NULL
day	NULL
0	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Replication	NULL
potential	NULL
with	NULL
0	NULL
,	NULL
100	NULL
,	NULL
and	NULL
1,000	NULL
ng	NULL
of	NULL
dox	NULL
per	NULL
ml	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Effect	NULL
of	NULL
delayed	NULL
addition	NULL
of	NULL
dox	NULL
(	NULL
1,000	NULL
ng/m	NULL
!	NULL
)	NULL

at	NULL
day	NULL
3	NULL
after	NULL
infection	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Infected	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
1,000	NULL
ng	NULL
of	NULL
dox	NULL
per	NULL
ml	NULL
for	NULL
3	NULL
days	NULL
,	NULL
at	NULL
which	NULL
point	NULL
the	NULL
cells	NULL
were	NULL
washed	NULL
and	NULL
incubated	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
dox	NULL
.	NULL

(	NULL
D	NULL
)	NULL
Infected	NULL
cells	NULL
were	NULL
maintained	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
dox	NULL
and	NULL
either	NULL
the	NULL
Pro	NULL
inhibitor	NULL
SQV	NULL
(	NULL
200	NULL
nM	NULL
)	NULL
or	NULL
the	NULL
RT	NULL
inhibitor	NULL
AZT	NULL
(	NULL
1	NULL
wM	NULL
)	NULL
.	NULL

984	NULL
VERHOEF	NULL
ET	NULL
AL	NULL
.	NULL

TABLE	NULL
2	NULL
.	NULL

Transient	NULL
HIV-rtTA	NULL
production	NULL
in	NULL
C33	NULL
and	NULL
SupT1	NULL
cells	NULL
HIV-rtTA	NULL
production	NULL
(	NULL
pg	NULL
of	NULL
CA-p24	NULL
per	NULL
ml	NULL
)	NULL
*	NULL
Th	NULL
cepa	NULL
=CMV-rtTA	NULL
+CMV-rtTA	NULL
variant	NULL
-dox	NULL
+dox	NULL
_	NULL
.	NULL

F014	NULL
-dox	NULL
+dox	NULL
.	NULL

F014	NULL
induction	NULL
induction	NULL
C33A	NULL
cells	NULL
KWK	NULL
11,600	NULL
545,000	NULL
47	NULL
91,500	NULL
715,000	NULL
7.8	NULL
SWS	NULL
11,350	NULL
560,000	NULL
49	NULL
49,500	NULL
560,000	NULL
11.3	NULL
KYK	NULL
4,850	NULL
580,000	NULL
120	NULL
47,500	NULL
500,000	NULL
10.5	NULL
SYS	NULL
5,950	NULL
455,000	NULL
76	NULL
32,500	NULL
520,000	NULL
16	NULL
LAI	NULL
635,000	NULL
520,000	NULL
0.8	NULL
SupT1	NULL
cells	NULL
KWK	NULL
110	NULL
-	NULL
54,000	NULL
491	NULL
SWS	NULL
30	NULL
65,000	NULL
2,167	NULL
KYK	NULL
10	NULL
39,000	NULL
3,900	NULL
SYS	NULL
20	NULL
7,800	NULL
390	NULL
``	NULL
Production	NULL
was	NULL
measured	NULL
for	NULL
the	NULL
variants	NULL
with	NULL
(	NULL
+	NULL
)	NULL
or	NULL
without	NULL
(	NULL
-	NULL
)	NULL
dox	NULL
and	NULL
CMV-rtTA	NULL
as	NULL
indicated	NULL
.	NULL

assay	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
.	NULL

We	NULL
next	NULL
analyzed	NULL
virus	NULL
replication	NULL
kinetics	NULL
when	NULL
dox	NULL
was	NULL
added	NULL
3	NULL
days	NULL
after	NULL
infection	NULL
of	NULL
the	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

This	NULL
resulted	NULL
in	NULL
a	NULL
delay	NULL
of	NULL
virus	NULL
production	NULL
of	NULL
approximately	NULL
3	NULL
days	NULL
.	NULL

In	NULL
the	NULL
absence	NULL
of	NULL
dox	NULL
,	NULL
the	NULL
HIV-rtTA	NULL
virus	NULL
can	NULL
still	NULL
infect	NULL
cells	NULL
,	NULL
reverse	NULL
transcribe	NULL
its	NULL
RNA	NULL
genome	NULL
,	NULL
and	NULL
integrate	NULL
the	NULL
DNA	NULL
into	NULL
the	NULL
host	NULL
genome	NULL
.	NULL

In	NULL
other	NULL
words	NULL
,	NULL
the	NULL
provirus	NULL
form	NULL
can	NULL
be	NULL
established	NULL
,	NULL
but	NULL
replication	NULL
is	NULL
blocked	NULL
at	NULL
the	NULL
level	NULL
of	NULL
viral	NULL
transcription	NULL
.	NULL

These	NULL
latently	NULL
infected	NULL
cells	NULL
will	NULL
remain	NULL
present	NULL
in	NULL
the	NULL
culture	NULL
and	NULL
can	NULL
be	NULL
activated	NULL
by	NULL
dox	NULL
after	NULL
3	NULL
days	NULL
to	NULL
produce	NULL
new	NULL
,	NULL
infectious	NULL
particles	NULL
.	NULL

A	NULL
key	NULL
feature	NULL
of	NULL
the	NULL
Tet	NULL
system	NULL
is	NULL
that	NULL
it	NULL
provides	NULL
reversible	NULL
regulation	NULL
.	NULL

To	NULL
test	NULL
this	NULL
,	NULL
SupT1	NULL
cells	NULL
were	NULL
infected	NULL
with	NULL
the	NULL
SWS	NULL
virus	NULL
and	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
dox	NULL
(	NULL
Fig	NULL
.	NULL

4C	NULL
)	NULL
.	NULL

At	NULL
day	NULL
3	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
washed	NULL
to	NULL
remove	NULL
extracellular	NULL
dox	NULL
and	NULL
resuspended	NULL
in	NULL
medium	NULL
either	NULL
with	NULL
or	NULL
without	NULL
dox	NULL
.	NULL

Indeed	NULL
,	NULL
replication	NULL
can	NULL
be	NULL
stopped	NULL
abruptly	NULL
by	NULL
the	NULL
removal	NULL
of	NULL
dox	NULL
.	NULL

These	NULL
combined	NULL
results	NULL
confirm	NULL
that	NULL
replication	NULL
of	NULL
the	NULL
HIV-rtTA	NULL
virus	NULL
is	NULL
absolutely	NULL
dependent	NULL
on	NULL
dox	NULL
,	NULL
and	NULL
the	NULL
level	NULL
of	NULL
virus	NULL
replication	NULL
can	NULL
be	NULL
strictly	NULL
controlled	NULL
in	NULL
a	NULL
graded	NULL
and	NULL
reversible	NULL
manner	NULL
.	NULL

Gene	NULL
expression	NULL
characteristics	NULL
of	NULL
the	NULL
HIV-rtTA	NULL
variants	NULL
.	NULL

We	NULL
next	NULL
set	NULL
out	NULL
to	NULL
accurately	NULL
measure	NULL
the	NULL
level	NULL
of	NULL
gene	NULL
expression	NULL
and	NULL
virus	NULL
production	NULL
of	NULL
the	NULL
HIV-rtTA	NULL
variants	NULL
compared	NULL
with	NULL
the	NULL
wild-type	NULL
LAI	NULL
construct	NULL
.	NULL

These	NULL
experiments	NULL
were	NULL
performed	NULL
by	NULL
transient	NULL
transfection	NULL
of	NULL
C33	NULL
cells	NULL
,	NULL
which	NULL
allows	NULL
virus	NULL
production	NULL
without	NULL
replication	NULL
due	NULL
to	NULL
the	NULL
absence	NULL
of	NULL
appropriate	NULL
receptors	NULL
for	NULL
virus	NULL
entry	NULL
.	NULL

The	NULL
results	NULL
are	NULL
summarized	NULL
in	NULL
Table	NULL
2	NULL
.	NULL

We	NULL
measured	NULL
low	NULL
virus	NULL
production	NULL
for	NULL
all	NULL
HIV-rtTA	NULL
constructs	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
dox	NULL
,	NULL
ranging	NULL
from	NULL
4,850	NULL
to	NULL
11,600	NULL
pg	NULL
of	NULL
CA-p24	NULL
per	NULL
ml	NULL
.	NULL

By	NULL
comparing	NULL
the	NULL
KWK	NULL
and	NULL
SWS	NULL
versus	NULL
KYK	NULL
and	NULL
SYS	NULL
constructs	NULL
,	NULL
it	NULL
is	NULL
clear	NULL
that	NULL
the	NULL
wild-type	NULL
Tat	NULL
protein	NULL
makes	NULL
a	NULL
modest	NULL
,	NULL
twofold	NULL
contribution	NULL
to	NULL
gene	NULL
expression	NULL
without	NULL
dox	NULL
.	NULL

This	NULL
basal	NULL
activity	NULL
is	NULL
0.8	NULL
to	NULL
2.1	NULL
%	NULL
of	NULL
the	NULL
virus	NULL
production	NULL
measured	NULL
by	NULL
the	NULL
wild-type	NULL
LAI	NULL
plasmid	NULL
,	NULL
which	NULL
is	NULL
an	NULL
excellent	NULL
value	NULL
compared	NULL
with	NULL
the	NULL
``	NULL
leakiness	NULL
``	NULL
measured	NULL
in	NULL
transient	NULL
LTR-luc	NULL
assays	NULL
(	NULL
7	NULL
to	NULL
10	NULL
%	NULL
;	NULL
results	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Profound	NULL
dox	NULL
induction	NULL
was	NULL
measured	NULL
for	NULL
all	NULL
constructs	NULL
,	NULL
ranging	NULL
from	NULL
47-	NULL
to	NULL
120-fold	NULL
induction	NULL
over	NULL
the	NULL
level	NULL
of	NULL
basal	NULL
activity	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
virus	NULL
production	NULL
levels	NULL
(	NULL
455,000	NULL
to	NULL
J	NULL
.	NULL

580,000	NULL
pg	NULL
of	NULL
CA-p24	NULL
per	NULL
ml	NULL
)	NULL
are	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
LAI	NULL
,	NULL
indicating	NULL
that	NULL
gene	NULL
expression	NULL
and	NULL
virion	NULL
production	NULL
are	NULL
efficiently	NULL
executed	NULL
by	NULL
the	NULL
HIV-rtTA	NULL
variants	NULL
.	NULL

Comparable	NULL
results	NULL
were	NULL
recently	NULL
presented	NULL
for	NULL
SIV	NULL
constructs	NULL
with	NULL
a	NULL
similarly	NULL
modified	NULL
LTR	NULL
promoter	NULL
(	NULL
55	NULL
)	NULL
.	NULL

Consistent	NULL
with	NULL
the	NULL
replication	NULL
ranking	NULL
order	NULL
of	NULL
the	NULL
HIV-rtTA	NULL
variants	NULL
,	NULL
SYS	NULL
produced	NULL
the	NULL
least	NULL
amount	NULL
of	NULL
virus	NULL
.	NULL

Establishment	NULL
of	NULL
an	NULL
rtTA-fetO	NULL
autoregulatory	NULL
loop	NULL
.	NULL

The	NULL
previous	NULL
results	NULL
indicate	NULL
that	NULL
gene	NULL
expression	NULL
and	NULL
replication	NULL
of	NULL
HIV-rtTA	NULL
are	NULL
strictly	NULL
dependent	NULL
on	NULL
dox	NULL
.	NULL

The	NULL
excellent	NULL
performance	NULL
of	NULL
the	NULL
HIV-rtTA	NULL
viruses	NULL
is	NULL
novel	NULL
due	NULL
,	NULL
at	NULL
least	NULL
in	NULL
part	NULL
,	NULL
to	NULL
the	NULL
use	NULL
of	NULL
the	NULL
rtTA-S2	NULL
reagent	NULL
,	NULL
which	NULL
was	NULL
shown	NULL
to	NULL
exhibit	NULL
no	NULL
measurable	NULL
basal	NULL
activity	NULL
in	NULL
the	NULL
uninduced	NULL
state	NULL
(	NULL
48	NULL
)	NULL
.	NULL

More-over	NULL
,	NULL
we	NULL
have	NULL
placed	NULL
rtTA	NULL
expression	NULL
under	NULL
control	NULL
of	NULL
an	NULL
rtTA-regulated	NULL
LTR	NULL
promoter	NULL
,	NULL
a	NULL
situation	NULL
that	NULL
mimics	NULL
the	NULL
natural	NULL
autoregulatory	NULL
loop	NULL
of	NULL
the	NULL
TAR-Tat	NULL
axis	NULL
.	NULL

This	NULL
means	NULL
that	NULL
both	NULL
the	NULL
activity	NULL
of	NULL
rtTA	NULL
and	NULL
its	NULL
synthesis	NULL
are	NULL
dox	NULL
dependent	NULL
.	NULL

Thus	NULL
,	NULL
only	NULL
minute	NULL
amounts	NULL
of	NULL
rtTA	NULL
protein	NULL
will	NULL
be	NULL
present	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
dox	NULL
,	NULL
resulting	NULL
in	NULL
an	NULL
extremely	NULL
low	NULL
basal	NULL
level	NULL
of	NULL
gene	NULL
expression	NULL
,	NULL
and	NULL
consequently	NULL
a	NULL
more-pro-found	NULL
dox	NULL
induction	NULL
.	NULL

In	NULL
other	NULL
Tet-controlled	NULL
gene	NULL
expression	NULL
systems	NULL
,	NULL
the	NULL
tTA	NULL
or	NULL
rtTA	NULL
protein	NULL
is	NULL
produced	NULL
in	NULL
a	NULL
constitutive	NULL
manner	NULL
from	NULL
a	NULL
second	NULL
locus	NULL
,	NULL
e.g	NULL
.	NULL

,	NULL
the	NULL
CMV-rtTA	NULL
plasmid	NULL
,	NULL
which	NULL
causes	NULL
a	NULL
significant	NULL
level	NULL
of	NULL
gene	NULL
activation	NULL
in	NULL
the	NULL
off	NULL
state	NULL
.	NULL

We	NULL
next	NULL
designed	NULL
an	NULL
experiment	NULL
to	NULL
critically	NULL
test	NULL
whether	NULL
an	NULL
autoregulatory	NULL
loop	NULL
is	NULL
established	NULL
in	NULL
HIV-rtTA	NULL
.	NULL

We	NULL
mimicked	NULL
the	NULL
regular	NULL
Tet	NULL
system	NULL
by	NULL
cotransfection	NULL
of	NULL
HIV-rtTA	NULL
with	NULL
CMV-rtTA	NULL
.	NULL

The	NULL
latter	NULL
plasmid	NULL
will	NULL
produce	NULL
a	NULL
constitutive	NULL
level	NULL
of	NULL
rtTA	NULL
protein	NULL
(	NULL
even	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
dox	NULL
)	NULL
,	NULL
which	NULL
is	NULL
expected	NULL
to	NULL
enhance	NULL
the	NULL
level	NULL
of	NULL
virus	NULL
production	NULL
in	NULL
the	NULL
uninduced	NULL
state	NULL
.	NULL

This	NULL
is	NULL
indeed	NULL
what	NULL
we	NULL
observed	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

The	NULL
uninduced	NULL
level	NULL
of	NULL
virus	NULL
production	NULL
was	NULL
increased	NULL
5-	NULL
to	NULL
10-fold	NULL
with	NULL
CMV-rtTA	NULL
.	NULL

The	NULL
results	NULL
in	NULL
Table	NULL
2	NULL
also	NULL
indicate	NULL
that	NULL
additional	NULL
synthesis	NULL
of	NULL
rtTA	NULL
protein	NULL
from	NULL
the	NULL
cotransfected	NULL
CMV-rtTA	NULL
plasmid	NULL
does	NULL
not	NULL
increase	NULL
the	NULL
level	NULL
of	NULL
virus	NULL
production	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
dox	NULL
,	NULL
indicating	NULL
that	NULL
all	NULL
HIV-rtTA	NULL
constructs	NULL
are	NULL
able	NULL
to	NULL
produce	NULL
saturating	NULL
amounts	NULL
of	NULL
rtTA	NULL
frans-activator	NULL
.	NULL

Due	NULL
to	NULL
increased	NULL
basal	NULL
expression	NULL
levels	NULL
in	NULL
cotransfections	NULL
with	NULL
CMV-rtTA	NULL
,	NULL
we	NULL
measured	NULL
only	NULL
8-	NULL
to	NULL
16-fold	NULL
dox	NULL
induction	NULL
levels	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
these	NULL
results	NULL
are	NULL
very	NULL
similar	NULL
to	NULL
the	NULL
results	NULL
obtained	NULL
with	NULL
the	NULL
corresponding	NULL
LTR-lue	NULL
constructs	NULL
(	NULL
K.	NULL
Verhoef	NULL
et	NULL
al	NULL
.	NULL

,	NULL
manuscript	NULL
in	NULL
preparation	NULL
)	NULL
.	NULL

These	NULL
LTR-luc	NULL
transfection	NULL
experiments	NULL
also	NULL
revealed	NULL
that	NULL
higher	NULL
dox	NULL
induction	NULL
levels	NULL
(	NULL
up	NULL
to	NULL
80-fold	NULL
)	NULL
can	NULL
be	NULL
obtained	NULL
in	NULL
the	NULL
T-cell	NULL
line	NULL
SupT1	NULL
.	NULL

Although	NULL
we	NULL
currently	NULL
do	NULL
not	NULL
understand	NULL
this	NULL
effect	NULL
,	NULL
the	NULL
responsiveness	NULL
of	NULL
the	NULL
Tet	NULL
system	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
differ	NULL
in	NULL
different	NULL
cell	NULL
types	NULL
(	NULL
27	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
tested	NULL
all	NULL
four	NULL
HIV-rtTA	NULL
variants	NULL
in	NULL
SupT1	NULL
cells	NULL
.	NULL

The	NULL
transfected	NULL
cells	NULL
were	NULL
cultured	NULL
with	NULL
or	NULL
without	NULL
dox	NULL
,	NULL
and	NULL
virus	NULL
production	NULL
was	NULL
measured	NULL
at	NULL
2	NULL
days	NULL
posttransfection	NULL
.	NULL

The	NULL
latter	NULL
point	NULL
is	NULL
critical	NULL
because	NULL
SupT1	NULL
cells	NULL
support	NULL
virus	NULL
replication	NULL
,	NULL
which	NULL
will	NULL
eventually	NULL
disturb	NULL
the	NULL
transient	NULL
expression	NULL
data	NULL
.	NULL

However	NULL
,	NULL
we	NULL
have	NULL
demonstrated	NULL
previously	NULL
that	NULL
replication	NULL
does	NULL
not	NULL
contribute	NULL
to	NULL
virus	NULL
production	NULL
measured	NULL
at	NULL
day	NULL
2	NULL
(	NULL
15	NULL
)	NULL
,	NULL
and	NULL
the	NULL
transient	NULL
virus	NULL
production	NULL
results	NULL
are	NULL
summarized	NULL
in	NULL
Table	NULL
2	NULL
.	NULL

Indeed	NULL
,	NULL
a	NULL
more	NULL
profound	NULL
dox	NULL
effect	NULL
was	NULL
measured	NULL
in	NULL
SupT1	NULL
cells	NULL
,	NULL
an	NULL
effect	NULL
ranging	NULL
from	NULL
390-	NULL
to	NULL
3,900-fold	NULL
induction	NULL
for	NULL
the	NULL
different	NULL
HIV-rtTA	NULL
constructs	NULL
.	NULL

These	NULL
values	NULL
are	NULL
somewhat	NULL
inaccurate	NULL
because	NULL
of	NULL
the	NULL
extremely	NULL
low	NULL
level	NULL
of	NULL
virus	NULL
production	NULL
in	NULL
Vor	NULL
.	NULL

75	NULL
,	NULL
2001	NULL
the	NULL
uninduced	NULL
state	NULL
,	NULL
which	NULL
hardly	NULL
exceeds	NULL
the	NULL
cutoff	NULL
value	NULL
of	NULL
the	NULL
CA-p24	NULL
assay	NULL
.	NULL

However	NULL
,	NULL
it	NULL
is	NULL
obvious	NULL
that	NULL
dox	NULL
inducibility	NULL
is	NULL
5-	NULL
to	NULL
10-fold	NULL
more	NULL
profound	NULL
in	NULL
SupT1	NULL
cells	NULL
than	NULL
in	NULL
C33A	NULL
cells	NULL
.	NULL

The	NULL
combined	NULL
effects	NULL
of	NULL
the	NULL
autoregulatory	NULL
loop	NULL
established	NULL
in	NULL
HIV-rtTA	NULL
and	NULL
the	NULL
T-cell-specific	NULL
augmentation	NULL
of	NULL
the	NULL
dox	NULL
response	NULL
result	NULL
in	NULL
rather	NULL
dramatic	NULL
induction	NULL
levels	NULL
.	NULL

In	NULL
SupT1	NULL
cells	NULL
,	NULL
an	NULL
extremely	NULL
low	NULL
basal	NULL
level	NULL
of	NULL
virus	NULL
production	NULL
is	NULL
measured	NULL
,	NULL
which	NULL
is	NULL
estimated	NULL
to	NULL
be	NULL
approximately	NULL
0.03	NULL
to	NULL
0.2	NULL
%	NULL
of	NULL
the	NULL
dox-induced	NULL
state	NULL
.	NULL

Safety	NULL
issues	NULL
.	NULL

The	NULL
finding	NULL
that	NULL
HIV-rtTA	NULL
has	NULL
an	NULL
extremely	NULL
low	NULL
level	NULL
of	NULL
virus	NULL
expression	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
dox	NULL
seems	NULL
the	NULL
ideal	NULL
situation	NULL
concerning	NULL
the	NULL
safety	NULL
of	NULL
a	NULL
vaccine	NULL
strain	NULL
.	NULL

We	NULL
performed	NULL
some	NULL
additional	NULL
assays	NULL
to	NULL
address	NULL
safety	NULL
aspects	NULL
.	NULL

First	NULL
,	NULL
we	NULL
screened	NULL
for	NULL
leaky	NULL
virus	NULL
replication	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
dox	NULL
in	NULL
prolonged	NULL
cultures	NULL
.	NULL

For	NULL
instance	NULL
,	NULL
the	NULL
SupT1	NULL
cultures	NULL
that	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
four	NULL
different	NULL
HIV-rtTA	NULL
constructs	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
were	NULL
maintained	NULL
up	NULL
to	NULL
day	NULL
170	NULL
,	NULL
but	NULL
no	NULL
virus	NULL
production	NULL
was	NULL
measured	NULL
.	NULL

Similarly	NULL
,	NULL
no	NULL
replicating	NULL
virus	NULL
was	NULL
observed	NULL
in	NULL
primary	NULL
cell	NULL
cultures	NULL
without	NULL
dox	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Second	NULL
,	NULL
HIV-rtTA	NULL
virus	NULL
spreading	NULL
in	NULL
SupT1	NULL
cultures	NULL
could	NULL
be	NULL
``	NULL
turned	NULL
off	NULL
``	NULL
effectively	NULL
by	NULL
the	NULL
removal	NULL
of	NULL
dox	NULL
(	NULL
see	NULL
,	NULL
e.g	NULL
.	NULL

,	NULL
Fig	NULL
.	NULL

4C	NULL
for	NULL
the	NULL
SWS	NULL
virus	NULL
)	NULL
,	NULL
without	NULL
any	NULL
sign	NULL
of	NULL
virus	NULL
production	NULL
.	NULL

Third	NULL
,	NULL
we	NULL
analyzed	NULL
the	NULL
sensitivity	NULL
of	NULL
the	NULL
HIV-rtTA	NULL
virus	NULL
to	NULL
antiretroviral	NULL
drugs	NULL
that	NULL
are	NULL
in	NULL
current	NULL
clinical	NULL
use	NULL
.	NULL

Because	NULL
we	NULL
did	NULL
not	NULL
alter	NULL
the	NULL
basic	NULL
set	NULL
of	NULL
viral	NULL
genes	NULL
in	NULL
HIV-rtTA	NULL
,	NULL
including	NULL
the	NULL
genes	NULL
encoding	NULL
protease	NULL
(	NULL
Pro	NULL
)	NULL
and	NULL
reverse	NULL
transcriptase	NULL
(	NULL
RT	NULL
)	NULL
,	NULL
these	NULL
viruses	NULL
are	NULL
expected	NULL
to	NULL
remain	NULL
fully	NULL
sensitive	NULL
to	NULL
well-known	NULL
drugs	NULL
that	NULL
target	NULL
these	NULL
essential	NULL
enzymes	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4D	NULL
,	NULL
replication	NULL
of	NULL
the	NULL
dox-dependent	NULL
SWS	NULL
virus	NULL
can	NULL
be	NULL
inhibited	NULL
efficiently	NULL
either	NULL
by	NULL
3'-azido-3'-deoxythymidine	NULL
(	NULL
AZT	NULL
;	NULL
a	NULL
nucle-oside	NULL
RT	NULL
inhibitor	NULL
)	NULL
or	NULL
saquinavir	NULL
(	NULL
SQV	NULL
;	NULL
a	NULL
Pro	NULL
inhibitor	NULL
)	NULL
.	NULL

These	NULL
experiments	NULL
may	NULL
be	NULL
viewed	NULL
as	NULL
the	NULL
first	NULL
safety	NULL
tests	NULL
of	NULL
these	NULL
putative	NULL
vaccine	NULL
strains	NULL
.	NULL

DISCUSSION	NULL
We	NULL
have	NULL
incorporated	NULL
the	NULL
Tet	NULL
regulatory	NULL
system	NULL
in	NULL
the	NULL
HIV-1	NULL
genome	NULL
such	NULL
that	NULL
virus	NULL
transcription	NULL
and	NULL
replication	NULL
can	NULL
now	NULL
be	NULL
controlled	NULL
from	NULL
the	NULL
outside	NULL
by	NULL
addition	NULL
of	NULL
a	NULL
nontoxic	NULL
inducer	NULL
molecule	NULL
such	NULL
as	NULL
dox	NULL
.	NULL

Specifically	NULL
,	NULL
we	NULL
constructed	NULL
replicating	NULL
HIV-1	NULL
variants	NULL
with	NULL
inactivating	NULL
mutations	NULL
in	NULL
both	NULL
arms	NULL
of	NULL
the	NULL
Tat-TAR	NULL
axis	NULL
through	NULL
replacement	NULL
with	NULL
the	NULL
rtTA-tetO	NULL
elements	NULL
of	NULL
the	NULL
Tet	NULL
system	NULL
.	NULL

Replication	NULL
experiments	NULL
in	NULL
a	NULL
T-cell	NULL
line	NULL
and	NULL
primary	NULL
cells	NULL
demonstrate	NULL
that	NULL
we	NULL
have	NULL
successfully	NULL
designed	NULL
dox-dependent	NULL
HIV-1	NULL
variants	NULL
.	NULL

Replication	NULL
of	NULL
these	NULL
designer	NULL
HIV-rtTA	NULL
viruses	NULL
is	NULL
regulatable	NULL
in	NULL
a	NULL
graded	NULL
and	NULL
reversible	NULL
manner	NULL
.	NULL

Although	NULL
leakiness	NULL
,	NULL
that	NULL
is	NULL
,	NULL
residual	NULL
activity	NULL
of	NULL
the	NULL
rtTA	NULL
activator	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
dox	NULL
,	NULL
has	NULL
been	NULL
a	NULL
problem	NULL
in	NULL
some	NULL
applications	NULL
of	NULL
the	NULL
rtTA	NULL
system	NULL
,	NULL
we	NULL
have	NULL
not	NULL
observed	NULL
any	NULL
virus	NULL
replication	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
dox	NULL
.	NULL

This	NULL
may	NULL
be	NULL
due	NULL
,	NULL
at	NULL
least	NULL
in	NULL
part	NULL
,	NULL
to	NULL
the	NULL
superior	NULL
performance	NULL
of	NULL
the	NULL
improved	NULL
rtTA-S2	NULL
protein	NULL
that	NULL
was	NULL
used	NULL
in	NULL
these	NULL
experiments	NULL
(	NULL
48	NULL
)	NULL
.	NULL

Another	NULL
possibility	NULL
is	NULL
that	NULL
expression	NULL
of	NULL
the	NULL
rtTA	NULL
trans-activator	NULL
in	NULL
the	NULL
viral	NULL
context	NULL
is	NULL
fully	NULL
dependent	NULL
on	NULL
the	NULL
presence	NULL
of	NULL
dox	NULL
.	NULL

Indeed	NULL
,	NULL
we	NULL
demonstrated	NULL
that	NULL
an	NULL
autoregulatory	NULL
loop	NULL
is	NULL
established	NULL
that	NULL
resembles	NULL
the	NULL
natural	NULL
situation	NULL
with	NULL
the	NULL
TAR-Tat	NULL
axis	NULL
.	NULL

This	NULL
mechanism	NULL
restricts	NULL
leakiness	NULL
or	NULL
dox-independent	NULL
replication	NULL
,	NULL
thereby	NULL
providing	NULL
an	NULL
additional	NULL
safety	NULL
feature	NULL
.	NULL

The	NULL
HIV-rtTA	NULL
viruses	NULL
have	NULL
some	NULL
unique	NULL
properties	NULL
that	NULL
make	NULL
them	NULL
ideal	NULL
reagents	NULL
for	NULL
a	NULL
variety	NULL
of	NULL
biological	NULL
experi-	NULL
CONDITIONAL	NULL
HIV-1	NULL
REPLICATION	NULL
_	NULL
985	NULL
ments	NULL
.	NULL

The	NULL
most	NULL
obvious	NULL
application	NULL
for	NULL
such	NULL
a	NULL
virus	NULL
is	NULL
in	NULL
the	NULL
field	NULL
of	NULL
live-attenuated	NULL
vaccines	NULL
,	NULL
and	NULL
a	NULL
similar	NULL
approach	NULL
may	NULL
be	NULL
used	NULL
to	NULL
put	NULL
control	NULL
over	NULL
other	NULL
retroviral	NULL
pathogens	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
HIV-2	NULL
and	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
)	NULL
,	NULL
pararetrovi-ruses	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
hepatitis	NULL
B	NULL
virus	NULL
)	NULL
,	NULL
or	NULL
DNA	NULL
viruses	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
herpesvirus	NULL
or	NULL
adenovirus	NULL
)	NULL
.	NULL

The	NULL
HIV-rtTA	NULL
viruses	NULL
will	NULL
improve	NULL
the	NULL
current	NULL
generation	NULL
of	NULL
live-attenuated	NULL
HIV-1	NULL
variants	NULL
as	NULL
potential	NULL
vaccine	NULL
strains	NULL
because	NULL
the	NULL
conditional	NULL
replication	NULL
provides	NULL
a	NULL
unique	NULL
safety	NULL
feature	NULL
.	NULL

Of	NULL
the	NULL
variants	NULL
constructed	NULL
in	NULL
this	NULL
study	NULL
,	NULL
the	NULL
SYS	NULL
variant	NULL
has	NULL
the	NULL
most	NULL
minimal	NULL
``	NULL
genotype	NULL
``	NULL
:	NULL
TAR~	NULL
Tat~	NULL
AU3	NULL
ANF-	NULL
Â«	NULL
kB	NULL
Anef	NULL
.	NULL

However	NULL
,	NULL
it	NULL
should	NULL
be	NULL
possible	NULL
to	NULL
further	NULL
delete	NULL
some	NULL
of	NULL
the	NULL
``	NULL
accessory	NULL
``	NULL
genes	NULL
such	NULL
as	NULL
vpr	NULL
and	NULL
vpu	NULL
.	NULL

The	NULL
absence	NULL
of	NULL
functional	NULL
Tat	NULL
seems	NULL
particularly	NULL
attractive	NULL
because	NULL
this	NULL
viral	NULL
protein	NULL
is	NULL
known	NULL
to	NULL
have	NULL
several	NULL
adverse	NULL
effects	NULL
on	NULL
the	NULL
host	NULL
cell	NULL
.	NULL

It	NULL
is	NULL
anticipated	NULL
that	NULL
HIV-rtTA	NULL
vaccine	NULL
viruses	NULL
will	NULL
be	NULL
able	NULL
to	NULL
induce	NULL
a	NULL
protective	NULL
immune	NULL
response	NULL
by	NULL
dox-induced	NULL
replication	NULL
,	NULL
after	NULL
which	NULL
replication	NULL
can	NULL
be	NULL
turned	NULL
off	NULL
by	NULL
the	NULL
withdrawal	NULL
of	NULL
dox	NULL
,	NULL
such	NULL
that	NULL
the	NULL
virus	NULL
will	NULL
remain	NULL
nonpathogenic	NULL
.	NULL

In	NULL
case	NULL
a	NULL
booster	NULL
vaccination	NULL
is	NULL
required	NULL
to	NULL
mount	NULL
an	NULL
optimal	NULL
immune	NULL
response	NULL
,	NULL
replication	NULL
can	NULL
be	NULL
switched	NULL
on	NULL
transiently	NULL
at	NULL
later	NULL
times	NULL
by	NULL
dox	NULL
.	NULL

Experiments	NULL
in	NULL
mice	NULL
indicate	NULL
that	NULL
the	NULL
expression	NULL
of	NULL
a	NULL
transgene	NULL
can	NULL
be	NULL
regulated	NULL
by	NULL
simply	NULL
adding	NULL
or	NULL
removing	NULL
dox	NULL
from	NULL
the	NULL
drinking	NULL
water	NULL
(	NULL
35	NULL
)	NULL
.	NULL

Our	NULL
tissue	NULL
culture	NULL
experiments	NULL
also	NULL
indicate	NULL
that	NULL
the	NULL
level	NULL
of	NULL
virus	NULL
replication	NULL
can	NULL
be	NULL
fine-tuned	NULL
by	NULL
varying	NULL
the	NULL
dox	NULL
level	NULL
.	NULL

We	NULL
demonstrate	NULL
that	NULL
the	NULL
HIV-rtTA	NULL
viruses	NULL
are	NULL
inhibited	NULL
by	NULL
antiviral	NULL
drugs	NULL
such	NULL
as	NULL
the	NULL
RT	NULL
inhibitor	NULL
AZT	NULL
and	NULL
the	NULL
Pro	NULL
inhibitor	NULL
SQV	NULL
.	NULL

These	NULL
viruses	NULL
will	NULL
await	NULL
extensive	NULL
replication	NULL
tests	NULL
to	NULL
verify	NULL
their	NULL
genetic	NULL
stability	NULL
,	NULL
followed	NULL
by	NULL
animal	NULL
tests	NULL
with	NULL
homologous	NULL
SIV	NULL
constructs	NULL
to	NULL
screen	NULL
for	NULL
their	NULL
pathogenic	NULL
potential	NULL
and	NULL
their	NULL
ability	NULL
to	NULL
induce	NULL
a	NULL
protective	NULL
immune	NULL
response	NULL
.	NULL

Because	NULL
the	NULL
TAR	NULL
RNA	NULL
and	NULL
fet	NULL
gene	NULL
may	NULL
have	NULL
become	NULL
nonessential	NULL
parts	NULL
of	NULL
the	NULL
HIV-rtTA	NULL
genome	NULL
,	NULL
these	NULL
elements	NULL
may	NULL
be	NULL
``	NULL
free	NULL
``	NULL
to	NULL
evolve	NULL
.	NULL

If	NULL
these	NULL
transcriptional	NULL
elements	NULL
have	NULL
no	NULL
other	NULL
function	NULL
in	NULL
the	NULL
viral	NULL
replication	NULL
cycle	NULL
,	NULL
one	NULL
would	NULL
predict	NULL
that	NULL
they	NULL
would	NULL
eventually	NULL
be	NULL
lost	NULL
either	NULL
by	NULL
deletion	NULL
or	NULL
by	NULL
accumulation	NULL
of	NULL
point	NULL
mutations	NULL
.	NULL

This	NULL
would	NULL
further	NULL
reduce	NULL
the	NULL
likelihood	NULL
of	NULL
a	NULL
wild-type-like	NULL
reversion	NULL
,	NULL
thereby	NULL
making	NULL
the	NULL
vaccine	NULL
strain	NULL
more	NULL
safe	NULL
.	NULL

However	NULL
,	NULL
the	NULL
situation	NULL
may	NULL
be	NULL
more	NULL
complex	NULL
since	NULL
additional	NULL
roles	NULL
have	NULL
been	NULL
proposed	NULL
for	NULL
both	NULL
motifs	NULL
(	NULL
reviewed	NULL
in	NULL
reference	NULL
6	NULL
)	NULL
.	NULL

This	NULL
is	NULL
most	NULL
obvious	NULL
for	NULL
the	NULL
TAR	NULL
motif	NULL
,	NULL
which	NULL
is	NULL
part	NULL
of	NULL
the	NULL
R	NULL
(	NULL
repeat	NULL
)	NULL
region	NULL
that	NULL
is	NULL
critical	NULL
in	NULL
strand	NULL
transfer	NULL
during	NULL
reverse	NULL
transcription	NULL
.	NULL

But	NULL
TAR	NULL
has	NULL
also	NULL
been	NULL
reported	NULL
to	NULL
contribute	NULL
to	NULL
RNA	NULL
packaging	NULL
in	NULL
virion	NULL
particles	NULL
.	NULL

The	NULL
Tat	NULL
protein	NULL
has	NULL
also	NULL
been	NULL
implicated	NULL
in	NULL
nontranscriptional	NULL
roles	NULL
,	NULL
e.g	NULL
.	NULL

,	NULL
during	NULL
mRNA	NULL
translation	NULL
and	NULL
the	NULL
process	NULL
of	NULL
reverse	NULL
transcription	NULL
(	NULL
13	NULL
,	NULL
26	NULL
,	NULL
28	NULL
,	NULL
44	NULL
)	NULL
.	NULL

Prolonged	NULL
culture	NULL
experiments	NULL
and	NULL
the	NULL
analysis	NULL
of	NULL
revertant	NULL
viruses	NULL
may	NULL
provide	NULL
more	NULL
insight	NULL
into	NULL
some	NULL
of	NULL
these	NULL
possibilities	NULL
.	NULL

The	NULL
HIV-1	NULL
TAR-Tat	NULL
axis	NULL
was	NULL
successfully	NULL
replaced	NULL
by	NULL
the	NULL
tetO-rtTA	NULL
system	NULL
,	NULL
and	NULL
the	NULL
latter	NULL
elements	NULL
appear	NULL
to	NULL
have	NULL
become	NULL
essential	NULL
viral	NULL
functions	NULL
.	NULL

This	NULL
may	NULL
preclude	NULL
the	NULL
spontaneous	NULL
loss	NULL
of	NULL
these	NULL
exogenous	NULL
elements	NULL
by	NULL
simple	NULL
deletion	NULL
,	NULL
thereby	NULL
enhancing	NULL
the	NULL
genetic	NULL
stability	NULL
of	NULL
vaccine	NULL
strains	NULL
based	NULL
on	NULL
HIV-rtTA	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
the	NULL
current	NULL
HIV-rtTA	NULL
viruses	NULL
do	NULL
replicate	NULL
suboptimally	NULL
.	NULL

The	NULL
advantage	NULL
of	NULL
working	NULL
with	NULL
HIV	NULL
is	NULL
that	NULL
even	NULL
if	NULL
a	NULL
poorly	NULL
replicating	NULL
virus	NULL
is	NULL
identified	NULL
,	NULL
the	NULL
error-prone	NULL
nature	NULL
of	NULL
the	NULL
RT	NULL
enzyme	NULL
will	NULL
allow	NULL
for	NULL
the	NULL
generation	NULL
and	NULL
outgrowth	NULL
of	NULL
faster-replicating	NULL
variants	NULL
by	NULL
a	NULL
meth-	NULL
986	NULL
VERHOEF	NULL
ET	NULL
AL	NULL
.	NULL

od	NULL
termed	NULL
forced	NULL
evolution	NULL
(	NULL
7	NULL
,	NULL
37	NULL
)	NULL
.	NULL

This	NULL
evolutionary	NULL
refinement	NULL
of	NULL
the	NULL
initial	NULL
designer	NULL
HIV-rtTA	NULL
viruses	NULL
provides	NULL
a	NULL
powerful	NULL
genetic	NULL
method	NULL
to	NULL
identify	NULL
modified	NULL
forms	NULL
of	NULL
the	NULL
E.	NULL
coli-derived	NULL
rtTA	NULL
protein	NULL
and/or	NULL
the	NULL
tefO	NULL
sites	NULL
that	NULL
are	NULL
better	NULL
suited	NULL
for	NULL
their	NULL
transcription	NULL
function	NULL
in	NULL
a	NULL
eukaryotic	NULL
background	NULL
.	NULL

Consistent	NULL
with	NULL
this	NULL
idea	NULL
,	NULL
we	NULL
recently	NULL
observed	NULL
improved	NULL
replication	NULL
of	NULL
the	NULL
HIV-rtTA	NULL
viruses	NULL
in	NULL
long-term	NULL
infection	NULL
experiments	NULL
,	NULL
apparently	NULL
without	NULL
repair	NULL
of	NULL
the	NULL
Tat-TAR	NULL
axis	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
Rainer	NULL
Loew	NULL
and	NULL
Maz	NULL
Hasan	NULL
for	NULL
providing	NULL
several	NULL
re	NULL
agents	NULL
of	NULL
the	NULL
Tet	NULL
system	NULL
.	NULL

We	NULL
thank	NULL
Wim	NULL
van	NULL
Est	NULL
for	NULL
excellent	NULL
artwork	NULL
.	NULL

Research	NULL
within	NULL
the	NULL
Berkhout	NULL
laboratory	NULL
is	NULL
sponsored	NULL
by	NULL
the	NULL
Dutch	NULL
AIDS	NULL
Fund	NULL
(	NULL
AIDS	NULL
Fonds	NULL
,	NULL
Amsterdam	NULL
,	NULL
The	NULL
Netherlands	NULL
)	NULL
,	NULL
the	NULL
Dutch	NULL
Cancer	NULL
Society	NULL
(	NULL
KWF	NULL
,	NULL
Amsterdam	NULL
,	NULL
The	NULL
Netherlands	NULL
)	NULL
,	NULL
the	NULL
Technology	NULL
Foundation	NULL
(	NULL
STW	NULL
,	NULL
Utrecht	NULL
,	NULL
The	NULL
Netherlands	NULL
)	NULL
,	NULL
and	NULL
the	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
(	NULL
NIH	NULL
,	NULL
Bethesda	NULL
,	NULL
Md	NULL
.	NULL
)	NULL

.	NULL

G.M	NULL
.	NULL

was	NULL
supported	NULL
by	NULL
EMBO	NULL
and	NULL
HFSP	NULL
fellowships	NULL
,	NULL
and	NULL
K.V	NULL
.	NULL

was	NULL
supported	NULL
by	NULL
a	NULL
short-term	NULL
EMBO	NULL
fellowship	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

REFERENCES	NULL
.	NULL

Almond	NULL
,	NULL
N.	NULL
,	NULL
K.	NULL
Kent	NULL
,	NULL
M.	NULL
Cranage	NULL
,	NULL
E.	NULL
Rud	NULL
,	NULL
B.	NULL
Clarke	NULL
,	NULL
and	NULL
E.	NULL
J.	NULL
Stott	NULL
.	NULL

1995	NULL
.	NULL

Protection	NULL
by	NULL
attenuated	NULL
simian	NULL
immunodeficiency	NULL
virus	NULL
in	NULL
macaques	NULL
against	NULL
challenge	NULL
with	NULL
virus-infected	NULL
cells	NULL
.	NULL

Lancet	NULL
345:1342-1344.	NULL
.	NULL

Baba	NULL
,	NULL
T.	NULL
W.	NULL
,	NULL
V.	NULL
Liska	NULL
,	NULL
A.	NULL
H.	NULL
Khimani	NULL
,	NULL
N.	NULL
B.	NULL
Ray	NULL
,	NULL
P.	NULL
J.	NULL
Dailey	NULL
,	NULL
D.	NULL
Penninck	NULL
,	NULL
R.	NULL
Bronson	NULL
,	NULL
M.	NULL
F.	NULL
Greene	NULL
,	NULL
H.	NULL
M.	NULL
McClure	NULL
,	NULL
L.	NULL
N.	NULL
Martin	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Rup-recht	NULL
.	NULL

1999	NULL
.	NULL

Live	NULL
attenuated	NULL
,	NULL
multiply	NULL
deleted	NULL
simian	NULL
immunodeficiency	NULL
virus	NULL
causes	NULL
AIDS	NULL
in	NULL
infant	NULL
and	NULL
adult	NULL
macaques	NULL
.	NULL

Nat	NULL
.	NULL

Med	NULL
.	NULL

5:194-203.	NULL
.	NULL

Back	NULL
,	NULL
N.	NULL
K.	NULL
T.	NULL
,	NULL
M.	NULL
Nijhuis	NULL
,	NULL
W.	NULL
Keulen	NULL
,	NULL
C.	NULL
A	NULL
.	NULL

B.	NULL
Boucher	NULL
,	NULL
B	NULL
.	NULL

B.	NULL
Oude	NULL
Essink	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
P.	NULL
van	NULL
Kuilenburg	NULL
,	NULL
A.	NULL
H.	NULL
Van	NULL
Gennip	NULL
,	NULL
and	NULL
B.	NULL
Berkhout	NULL
.	NULL

1996	NULL
.	NULL

Reduced	NULL
replication	NULL
of	NULL
3TC-resistant	NULL
HIV-1	NULL
variants	NULL
in	NULL
primary	NULL
cells	NULL
due	NULL
to	NULL
a	NULL
proces-sivity	NULL
defect	NULL
of	NULL
the	NULL
reverse	NULL
transcriptase	NULL
enzyme	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

15:4040-4049.	NULL
.	NULL

Baron	NULL
,	NULL
U.	NULL
,	NULL
M.	NULL
Gossen	NULL
,	NULL
and	NULL
H.	NULL
Bujard	NULL
.	NULL

1997	NULL
.	NULL

Tetracycline-controlled	NULL
tran	NULL
scription	NULL
in	NULL
eukaryotes	NULL
:	NULL
novel	NULL
transactivators	NULL
with	NULL
graded	NULL
transactivation	NULL
potential	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

25:2723-2729.	NULL
.	NULL

Baron	NULL
,	NULL
U.	NULL
,	NULL
and	NULL
H.	NULL
Bujard	NULL
.	NULL

2000	NULL
.	NULL

Tet	NULL
repressor-based	NULL
system	NULL
for	NULL
regulated	NULL
gene	NULL
expression	NULL
in	NULL
eukaryotic	NULL
cells	NULL
:	NULL
principles	NULL
and	NULL
advances	NULL
.	NULL

Methods	NULL
En-zymol	NULL
.	NULL

327:401-421.	NULL
.	NULL

Berkhout	NULL
,	NULL
B	NULL
.	NULL

2000	NULL
.	NULL

Multiple	NULL
biological	NULL
roles	NULL
associated	NULL
with	NULL
the	NULL
repeat	NULL
(	NULL
R	NULL
)	NULL
region	NULL
of	NULL
the	NULL
HIV-1	NULL
RNA	NULL
genome	NULL
.	NULL

Adv	NULL
.	NULL

Pharmacol	NULL
.	NULL

48:29-73.	NULL
.	NULL

Berkhout	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
A.	NULL
T.	NULL
Das	NULL
.	NULL

1999	NULL
.	NULL

Functional	NULL
analysis	NULL
of	NULL
RNA	NULL
signals	NULL
in	NULL
the	NULL
HIV-1	NULL
genome	NULL
by	NULL
forced	NULL
evolution	NULL
,	NULL
p.	NULL
249-275	NULL
.	NULL

In	NULL
J.	NULL
Barciszewski	NULL
and	NULL
B.	NULL
F.	NULL
C.	NULL
Clark	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
RNA	NULL
biochemistry	NULL
and	NULL
biotechnology	NULL
.	NULL

Kluwer	NULL
Academic	NULL
Publishers	NULL
,	NULL
Dordrecht	NULL
,	NULL
The	NULL
Netherlands	NULL
.	NULL

.	NULL

Berkhout	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
K.	NULL
T.	NULL
Jeang	NULL
.	NULL

1989	NULL
.	NULL

Transactivation	NULL
of	NULL
human	NULL
immunode-	NULL
ficiency	NULL
virus	NULL
type	NULL
1	NULL
is	NULL
sequence	NULL
specific	NULL
for	NULL
both	NULL
the	NULL
single-stranded	NULL
bulge	NULL
and	NULL
loop	NULL
of	NULL
the	NULL
frans-acting-responsive	NULL
hairpin	NULL
:	NULL
a	NULL
quantitative	NULL
analysis	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:5501-5504.	NULL
.	NULL

Berkhout	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
B.	NULL
Klaver	NULL
.	NULL

1993	NULL
.	NULL

In	NULL
vivo	NULL
selection	NULL
of	NULL
randomly	NULL
mutated	NULL
retroviral	NULL
genomes	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

21:5020-5024	NULL
.	NULL

Berkhout	NULL
,	NULL
B.	NULL
,	NULL
J.	NULL
van	NULL
Wamel	NULL
,	NULL
and	NULL
B.	NULL
Klaver	NULL
.	NULL

1995	NULL
.	NULL

Requirements	NULL
for	NULL
DNA	NULL
strand	NULL
transfer	NULL
during	NULL
reverse	NULL
transcription	NULL
in	NULL
mutant	NULL
HIV-1	NULL
virions	NULL
.	NULL

J.	NULL
Mol	NULL
.	NULL

Biol	NULL
.	NULL

252:59-69	NULL
.	NULL

Berkhout	NULL
,	NULL
B.	NULL
,	NULL
K.	NULL
Verhoef	NULL
,	NULL
J.	NULL
L.	NULL
B.	NULL
van	NULL
Wamel	NULL
,	NULL
and	NULL
N.	NULL
K.	NULL
T.	NULL
Back	NULL
.	NULL

1999	NULL
.	NULL

Genetic	NULL
instability	NULL
of	NULL
live	NULL
attenuated	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
vaccine	NULL
strains	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

73:1138-1145	NULL
.	NULL

Brown	NULL
,	NULL
P.	NULL
O	NULL
.	NULL

1997	NULL
.	NULL

Integration	NULL
,	NULL
p.	NULL
161-204	NULL
.	NULL

In	NULL
J.	NULL
M.	NULL
Coffin	NULL
,	NULL
S.	NULL
H.	NULL
Hughes	NULL
,	NULL
and	NULL
H.	NULL
E.	NULL
Varmus	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Retroviruses	NULL
.	NULL

Cold	NULL
Spring	NULL
Harbor	NULL
Laboratory	NULL
Press	NULL
,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
N.Y.	NULL
Cullen	NULL
,	NULL
B.	NULL
R.	NULL
1986	NULL
.	NULL

Trans-activation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
occurs	NULL
via	NULL
a	NULL
bimodal	NULL
mechanism	NULL
.	NULL

Cell	NULL
46:973-982	NULL
.	NULL

Daniel	NULL
,	NULL
M.	NULL
D.	NULL
,	NULL
F.	NULL
Kirchhoff	NULL
,	NULL
S.	NULL
C.	NULL
Czajak	NULL
,	NULL
P.	NULL
K.	NULL
Sehgal	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Desrosiers	NULL
.	NULL

1992	NULL
.	NULL

Protective	NULL
effects	NULL
of	NULL
a	NULL
live	NULL
attenuated	NULL
SIV	NULL
vaccine	NULL
with	NULL
a	NULL
deletion	NULL
in	NULL
the	NULL
nef	NULL
gene	NULL
.	NULL

Science	NULL
258:1938-1941	NULL
.	NULL

Das	NULL
,	NULL
A.	NULL
T.	NULL
,	NULL
B.	NULL
Klaver	NULL
,	NULL
and	NULL
B.	NULL
Berkhout	NULL
.	NULL

1995	NULL
.	NULL

Reduced	NULL
replication	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
mutants	NULL
that	NULL
use	NULL
reverse	NULL
transcription	NULL
primers	NULL
other	NULL
than	NULL
the	NULL
natural	NULL
tRNA	NULL
(	NULL
3Lys	NULL
)	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

69:3090-3097	NULL
.	NULL

Das	NULL
,	NULL
A.	NULL
T.	NULL
,	NULL
B.	NULL
Klaver	NULL
,	NULL
and	NULL
B.	NULL
Berkhout	NULL
.	NULL

1999	NULL
.	NULL

A	NULL
hairpin	NULL
structure	NULL
in	NULL
the	NULL
R	NULL
region	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
RNA	NULL
genome	NULL
is	NULL
instrumental	NULL
in	NULL
polyadenylation	NULL
site	NULL
selection	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

73:81-91	NULL
.	NULL

Deacon	NULL
,	NULL
N.	NULL
J.	NULL
,	NULL
A.	NULL
Tsykin	NULL
,	NULL
A.	NULL
Solomon	NULL
,	NULL
K.	NULL
Smith	NULL
,	NULL
M.	NULL
Ludford-Menting	NULL
,	NULL
D.	NULL
J.	NULL
Hooker	NULL
,	NULL
D.	NULL
A.	NULL
McPhee	NULL
,	NULL
A.	NULL
L.	NULL
Greenway	NULL
,	NULL
A.	NULL
Ellett	NULL
,	NULL
C.	NULL
Chatfield	NULL
,	NULL
V.	NULL
A.	NULL
Lawson	NULL
,	NULL
S.	NULL
Crowe	NULL
,	NULL
A.	NULL
Maerz	NULL
,	NULL
S.	NULL
Sonza	NULL
,	NULL
J.	NULL
Learmont	NULL
,	NULL
J.	NULL
S.	NULL
Sullivan	NULL
,	NULL
A.	NULL
Cunningham	NULL
,	NULL
D.	NULL
Dwyer	NULL
,	NULL
D.	NULL
Dowton	NULL
,	NULL
and	NULL
J	NULL
.	NULL

Mills	NULL
.	NULL

1995	NULL
.	NULL

Genomic	NULL
structure	NULL
of	NULL
an	NULL
attenuated	NULL
18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

J.	NULL
quasi	NULL
species	NULL
of	NULL
HIV-1	NULL
from	NULL
blood	NULL
transfusion	NULL
donor	NULL
and	NULL
recipients	NULL
.	NULL

Science	NULL
270:988-991.	NULL
de	NULL
Ronde	NULL
,	NULL
A.	NULL
,	NULL
B.	NULL
Klaver	NULL
,	NULL
W.	NULL
Keulen	NULL
,	NULL
L.	NULL
Smit	NULL
,	NULL
and	NULL
J.	NULL
Goudsmit	NULL
.	NULL

1992	NULL
.	NULL

Natural	NULL
HIV-1	NULL
NEF	NULL
accelerates	NULL
virus	NULL
replication	NULL
in	NULL
primary	NULL
human	NULL
lymphocytes	NULL
.	NULL

Virology	NULL
188:391-395	NULL
.	NULL

Dingwall	NULL
,	NULL
C.	NULL
,	NULL
I.	NULL
Ernberg	NULL
,	NULL
M.	NULL
J.	NULL
Gait	NULL
,	NULL
S.	NULL
M.	NULL
Green	NULL
,	NULL
S.	NULL
Heaphy	NULL
,	NULL
J.	NULL
Karn	NULL
,	NULL
A.	NULL
D.	NULL
Lowe	NULL
,	NULL
M.	NULL
Singh	NULL
,	NULL
M.	NULL
A.	NULL
Skinner	NULL
,	NULL
and	NULL
R.	NULL
Valerio	NULL
.	NULL

1989	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
1	NULL
Tat	NULL
protein	NULL
binds	NULL
trans-activating-responsive	NULL
region	NULL
(	NULL
TAR	NULL
)	NULL
RNA	NULL
in	NULL
vitro	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86:6925-6929	NULL
.	NULL

Dyer	NULL
,	NULL
W.	NULL
B.	NULL
,	NULL
G.	NULL
S.	NULL
Ogg	NULL
,	NULL
M.-A	NULL
.	NULL

Demoitie	NULL
,	NULL
X.	NULL
Jin	NULL
,	NULL
A.	NULL
F.	NULL
Geczy	NULL
,	NULL
S.	NULL
L.	NULL
Rowland-Jones	NULL
,	NULL
A.	NULL
J.	NULL
McMichael	NULL
,	NULL
D.	NULL
F.	NULL
Nixon	NULL
,	NULL
and	NULL
J.	NULL
S.	NULL
Sullivan	NULL
.	NULL

1999	NULL
.	NULL

Strong	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
HIV	NULL
)	NULL
-specific	NULL
cytotoxic	NULL
T-lymphocyte	NULL
activity	NULL
in	NULL
Sydney	NULL
blood	NULL
bank	NULL
cohort	NULL
patients	NULL
infected	NULL
with	NULL
nef-defective	NULL
HIV	NULL
type	NULL
1	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

73:436-443	NULL
.	NULL

Feng	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
E.	NULL
C.	NULL
Holland	NULL
.	NULL

1988	NULL
.	NULL

HIV-1	NULL
tat	NULL
trans-activation	NULL
requires	NULL
the	NULL
loop	NULL
sequence	NULL
within	NULL
tar	NULL
.	NULL

Nature	NULL
334:165-167	NULL
.	NULL

Fisher	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
S.	NULL
P.	NULL
Goff	NULL
.	NULL

1998	NULL
.	NULL

Mutational	NULL
analysis	NULL
of	NULL
stem-loops	NULL
in	NULL
the	NULL
RNA	NULL
packaging	NULL
signal	NULL
of	NULL
the	NULL
Moloney	NULL
murine	NULL
leukemia	NULL
virus	NULL
.	NULL

Virology	NULL
244	NULL
:	NULL
133-145	NULL
.	NULL

Gossen	NULL
,	NULL
M.	NULL
,	NULL
S.	NULL
Freundlieb	NULL
,	NULL
G.	NULL
Bender	NULL
,	NULL
G.	NULL
Muller	NULL
,	NULL
W.	NULL
Hillen	NULL
,	NULL
and	NULL
H.	NULL
Bujard	NULL
.	NULL

1995	NULL
.	NULL

Transcriptional	NULL
activation	NULL
by	NULL
tetracyclines	NULL
in	NULL
mammalian	NULL
cells	NULL
.	NULL

Science	NULL
268:1766-1769	NULL
.	NULL

Gossen	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
H.	NULL
Bujard	NULL
.	NULL

1992	NULL
.	NULL

Tight	NULL
control	NULL
of	NULL
gene	NULL
expression	NULL
in	NULL
mammalian	NULL
cells	NULL
by	NULL
tetracycline-responsive	NULL
promoters	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89:5547-5551	NULL
.	NULL

Greenough	NULL
,	NULL
T.	NULL
C.	NULL
,	NULL
J.	NULL
L.	NULL
Sullivan	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Desrosiers	NULL
.	NULL

1999	NULL
.	NULL

Declining	NULL
CD4	NULL
T-cell	NULL
counts	NULL
in	NULL
a	NULL
person	NULL
infected	NULL
with	NULL
nef-deleted	NULL
HIV-1	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

340:236-237	NULL
.	NULL

Harrich	NULL
,	NULL
D.	NULL
,	NULL
C.	NULL
Ulich	NULL
,	NULL
L.	NULL
F.	NULL
Garcia-Martinez	NULL
,	NULL
and	NULL
R.	NULL
B.	NULL
Gaynor	NULL
.	NULL

1997	NULL
.	NULL

Tat	NULL
is	NULL
required	NULL
for	NULL
efficient	NULL
HIV-1	NULL
reverse	NULL
transcription	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

16:1224-1235	NULL
.	NULL

Howe	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
B.	NULL
V.	NULL
Skryabin	NULL
,	NULL
S.	NULL
M.	NULL
Belcher	NULL
,	NULL
C.	NULL
A.	NULL
Zerillo	NULL
,	NULL
and	NULL
C.	NULL
Schmauss	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
responsiveness	NULL
of	NULL
a	NULL
tetracycline-sensitive	NULL
expression	NULL
system	NULL
differs	NULL
in	NULL
different	NULL
cell	NULL
lines	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270:14168-14174	NULL
.	NULL

Huang	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
A.	NULL
Joshi	NULL
,	NULL
R.	NULL
Willey	NULL
,	NULL
J.	NULL
Orenstein	NULL
,	NULL
and	NULL
K.	NULL
T.	NULL
Jeang	NULL
.	NULL

1994	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
viruses	NULL
regulated	NULL
by	NULL
alternative	NULL
trans-activators	NULL
:	NULL
genetic	NULL
evidence	NULL
for	NULL
a	NULL
novel	NULL
non-transcriptional	NULL
function	NULL
of	NULL
Tat	NULL
in	NULL
virion	NULL
infectivity	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

13:2886-2896	NULL
.	NULL

Ilyinskii	NULL
,	NULL
P.	NULL
O.	NULL
,	NULL
M.	NULL
D.	NULL
Daniel	NULL
,	NULL
M.	NULL
A.	NULL
Simon	NULL
,	NULL
A	NULL
.	NULL

A.	NULL
Lackner	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Desrosiers	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
role	NULL
of	NULL
the	NULL
upstream	NULL
U3	NULL
sequences	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
simian	NULL
immunodeficiency	NULL
virus-induced	NULL
AIDS	NULL
in	NULL
rhesus	NULL
monkeys	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

68:5933-5944	NULL
.	NULL

Ilyinskii	NULL
,	NULL
P.	NULL
O.	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Desrosiers	NULL
.	NULL

1998	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
sequence	NULL
element	NULL
immediately	NULL
upstream	NULL
of	NULL
the	NULL
polypurine	NULL
tract	NULL
that	NULL
is	NULL
essential	NULL
for	NULL
replication	NULL
of	NULL
simian	NULL
immunodeficiency	NULL
virus	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

17:3766-3774	NULL
.	NULL

Jeeninga	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
M.	NULL
Hoogenkamp	NULL
,	NULL
M.	NULL
Armand-Ugo	NULL
,	NULL
M.	NULL
de	NULL
Baar	NULL
,	NULL
K.	NULL
Verhoef	NULL
,	NULL
and	NULL
B.	NULL
Berkhout	NULL
.	NULL

2000	NULL
.	NULL

Functional	NULL
differences	NULL
between	NULL
the	NULL
LTR	NULL
transcriptional	NULL
promoters	NULL
of	NULL
HIV-1	NULL
subtypes	NULL
A	NULL
through	NULL
G.	NULL
J.	NULL
Virol	NULL
.	NULL

74:3740-3751	NULL
.	NULL

Johnson	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
J.	NULL
D.	NULL
Lifson	NULL
,	NULL
S.	NULL
C.	NULL
Czajak	NULL
,	NULL
K.	NULL
Stefano	NULL
Cole	NULL
,	NULL
K.	NULL
H.	NULL
Manson	NULL
,	NULL
R.	NULL
L.	NULL
Glickman	NULL
,	NULL
J.	NULL
Q.	NULL
Yang	NULL
,	NULL
D.	NULL
C.	NULL
Montefiori	NULL
,	NULL
R.	NULL
C.	NULL
Montefioro	NULL
,	NULL
M.	NULL
S.	NULL
Wyand	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Desrosiers	NULL
.	NULL

1999	NULL
.	NULL

Highly	NULL
attenuated	NULL
vaccine	NULL
strains	NULL
of	NULL
simian	NULL
immunodeficiency	NULL
virus	NULL
protect	NULL
against	NULL
vaginal	NULL
challenge	NULL
:	NULL
inverse	NULL
relationship	NULL
of	NULL
degree	NULL
of	NULL
protection	NULL
with	NULL
level	NULL
of	NULL
attenuation	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

73	NULL
:	NULL
4952-4961	NULL
.	NULL

Kirchhoff	NULL
,	NULL
F.	NULL
,	NULL
T.	NULL
Greenough	NULL
,	NULL
D.	NULL
B.	NULL
Brettler	NULL
,	NULL
J.	NULL
L.	NULL
Sullivan	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Desrosiers	NULL
.	NULL

1995	NULL
.	NULL

Absence	NULL
of	NULL
intact	NULL
nef	NULL
sequences	NULL
in	NULL
a	NULL
long-term	NULL
survivor	NULL
with	NULL
nonprogressive	NULL
HIV-1	NULL
infection	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

332:228-232	NULL
.	NULL

Kirchhoff	NULL
,	NULL
F.	NULL
,	NULL
H.	NULL
W.	NULL
Kestler	NULL
IHH	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Desrosiers	NULL
.	NULL

1994	NULL
.	NULL

Upstream	NULL
U3	NULL
sequences	NULL
in	NULL
simian	NULL
immunodeficiency	NULL
virus	NULL
are	NULL
selectively	NULL
deleted	NULL
in	NULL
vivo	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
an	NULL
intact	NULL
nef	NULL
gene	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

68:2031-2037	NULL
.	NULL

Kistner	NULL
,	NULL
A.	NULL
,	NULL
M.	NULL
Gossen	NULL
,	NULL
F.	NULL
Zimmermann	NULL
,	NULL
J.	NULL
Jerecic	NULL
,	NULL
C.	NULL
Ullmer	NULL
,	NULL
H.	NULL
Lubbert	NULL
,	NULL
and	NULL
H.	NULL
Bujard	NULL
.	NULL

1996	NULL
.	NULL

Doxycycline-mediated	NULL
quantitative	NULL
and	NULL
tissue-specific	NULL
control	NULL
of	NULL
gene	NULL
expression	NULL
in	NULL
transgenic	NULL
mice	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93:10933-10938	NULL
.	NULL

Klaver	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
B.	NULL
Berkhout	NULL
.	NULL

1994	NULL
.	NULL

Comparison	NULL
of	NULL
5	NULL
'	NULL
and	NULL
3	NULL
'	NULL
long	NULL
terminal	NULL
repeat	NULL
promoter	NULL
function	NULL
in	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

68	NULL
:	NULL
3830-3840	NULL
.	NULL

Klaver	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
B.	NULL
Berkhout	NULL
.	NULL

1994	NULL
.	NULL

Evolution	NULL
of	NULL
a	NULL
disrupted	NULL
TAR	NULL
RNA	NULL
hairpin	NULL
structure	NULL
in	NULL
the	NULL
HIV-1	NULL
virus	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

13:2650-2659	NULL
.	NULL

Klaver	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
B.	NULL
Berkhout	NULL
.	NULL

1994	NULL
.	NULL

Premature	NULL
strand	NULL
transfer	NULL
by	NULL
the	NULL
HIV-1	NULL
reverse	NULL
transcriptase	NULL
during	NULL
strong-stop	NULL
DNA	NULL
synthesis	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

22:137-144	NULL
.	NULL

Kozak	NULL
,	NULL
M.	NULL
1989	NULL
.	NULL

The	NULL
scanning	NULL
model	NULL
for	NULL
translation	NULL
:	NULL
an	NULL
update	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

108:229-241	NULL
.	NULL

Lohman	NULL
,	NULL
B.	NULL
L.	NULL
,	NULL
M.	NULL
B.	NULL
McChesney	NULL
,	NULL
C.	NULL
J.	NULL
Miller	NULL
,	NULL
E.	NULL
McGowan	NULL
,	NULL
S.	NULL
M.	NULL
Joye	NULL
,	NULL
K.	NULL
K.	NULL
van	NULL
Rompay	NULL
,	NULL
E.	NULL
Reay	NULL
,	NULL
L.	NULL
Antipa	NULL
,	NULL
N.	NULL
C.	NULL
Pedersen	NULL
,	NULL
and	NULL
M.	NULL
L.	NULL
Marthas	NULL
.	NULL

1994	NULL
.	NULL

A	NULL
partially	NULL
attenuated	NULL
simian	NULL
immunodeficiency	NULL
virus	NULL
induces	NULL
host	NULL
immunity	NULL
that	NULL
correlates	NULL
with	NULL
resistance	NULL
to	NULL
pathogenic	NULL
virus	NULL
challenge	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

68	NULL
:	NULL
7021-7029	NULL
.	NULL

Maniatis	NULL
,	NULL
T.	NULL
,	NULL
E.	NULL
F.	NULL
Fritsch	NULL
,	NULL
and	NULL
J.	NULL
Sambrook	NULL
.	NULL

1982	NULL
.	NULL

Molecular	NULL
cloning	NULL
:	NULL
a	NULL
laboratory	NULL
manual	NULL
.	NULL

Cold	NULL
Spring	NULL
Harbor	NULL
Laboratory	NULL
,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
N.Y.	NULL
Mikaelian	NULL
,	NULL
I.	NULL
,	NULL
and	NULL
A	NULL
.	NULL

Sergeant	NULL
.	NULL

1992	NULL
.	NULL

A	NULL
general	NULL
and	NULL
fast	NULL
method	NULL
to	NULL
generate	NULL
Vor	NULL
.	NULL

75	NULL
,	NULL
2001	NULL
43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48.	NULL
multiple	NULL
site	NULL
directed	NULL
mutations	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

20:376	NULL
.	NULL

Peden	NULL
,	NULL
K.	NULL
,	NULL
M.	NULL
Emerman	NULL
,	NULL
and	NULL
L.	NULL
Montagnier	NULL
.	NULL

1991	NULL
.	NULL

Changes	NULL
in	NULL
growth	NULL
properties	NULL
on	NULL
passage	NULL
in	NULL
tissue	NULL
culture	NULL
of	NULL
viruses	NULL
derived	NULL
from	NULL
infectious	NULL
molecular	NULL
clones	NULL
of	NULL
HIV-1	NULL
;	NULL
aj	NULL
,	NULL
and	NULL
HIV-15	NULL
;	NULL
j.	NULL
Virology	NULL
185:661-672	NULL
.	NULL

SenGupta	NULL
,	NULL
D.	NULL
N.	NULL
,	NULL
B.	NULL
Berkhout	NULL
,	NULL
A.	NULL
Gatignol	NULL
,	NULL
A.	NULL
M.	NULL
Zhou	NULL
,	NULL
and	NULL
R.	NULL
H.	NULL
Silver-man	NULL
.	NULL

1990	NULL
.	NULL

Direct	NULL
evidence	NULL
for	NULL
translational	NULL
regulation	NULL
by	NULL
leader	NULL
RNA	NULL
and	NULL
Tat	NULL
protein	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
87:7492-7496	NULL
.	NULL

Shibata	NULL
,	NULL
R.	NULL
,	NULL
C.	NULL
Siemon	NULL
,	NULL
S.	NULL
C.	NULL
Czajak	NULL
,	NULL
R.	NULL
C.	NULL
Desrosiers	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
Martin	NULL
.	NULL

1997	NULL
.	NULL

Live	NULL
,	NULL
attenuated	NULL
simian	NULL
immunodeficiency	NULL
virus	NULL
vaccines	NULL
elicit	NULL
potent	NULL
resistance	NULL
against	NULL
a	NULL
challenge	NULL
with	NULL
a	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
chimeric	NULL
virus	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

71:8141-8148	NULL
.	NULL

Stahl-Hennig	NULL
,	NULL
C.	NULL
,	NULL
U.	NULL
Dittmer	NULL
,	NULL
T.	NULL
Nisslein	NULL
,	NULL
H.	NULL
Petry	NULL
,	NULL
E.	NULL
Jurkiewicz	NULL
,	NULL
D.	NULL
Fuchs	NULL
,	NULL
H.	NULL
Wachter	NULL
,	NULL
K.	NULL
Matz-Rensing	NULL
,	NULL
E.	NULL
M.	NULL
Kuhn	NULL
,	NULL
F.	NULL
J.	NULL
Kaup	NULL
,	NULL
E.	NULL
W.	NULL
Rud	NULL
,	NULL
and	NULL
G.	NULL
Hunsmann	NULL
.	NULL

1996	NULL
.	NULL

Rapid	NULL
development	NULL
of	NULL
vaccine	NULL
protection	NULL
in	NULL
macaques	NULL
by	NULL
live-attenuated	NULL
simian	NULL
immunodeficiency	NULL
virus	NULL
.	NULL

J.	NULL
Gen.	NULL
Virol	NULL
.	NULL

77:2969-2981	NULL
.	NULL

Ulich	NULL
,	NULL
C.	NULL
,	NULL
A.	NULL
Dunne	NULL
,	NULL
E.	NULL
Parry	NULL
,	NULL
C.	NULL
W.	NULL
Hooker	NULL
,	NULL
R.	NULL
B.	NULL
Gaynor	NULL
,	NULL
and	NULL
D.	NULL
Harrich	NULL
.	NULL

1999	NULL
.	NULL

Functional	NULL
domains	NULL
of	NULL
Tat	NULL
required	NULL
for	NULL
efficient	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
reverse	NULL
transcription	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

73:2499-2508	NULL
.	NULL

Urlinger	NULL
,	NULL
S.	NULL
,	NULL
U.	NULL
Baron	NULL
,	NULL
M.	NULL
Thellmann	NULL
,	NULL
M.	NULL
T.	NULL
Hasan	NULL
,	NULL
H.	NULL
Bujard	NULL
,	NULL
and	NULL
W.	NULL
Hillen	NULL
.	NULL

2000	NULL
.	NULL

Exploring	NULL
the	NULL
sequence	NULL
space	NULL
for	NULL
tetracycline-dependent	NULL
transcriptional	NULL
activators	NULL
:	NULL
novel	NULL
mutations	NULL
yield	NULL
expanded	NULL
range	NULL
and	NULL
sensitivity	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
97:7963-7968	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

CONDITIONAL	NULL
HIV-1	NULL
REPLICATION	NULL
-	NULL
987	NULL
van	NULL
Rompay	NULL
,	NULL
K.	NULL
K.	NULL
A.	NULL
,	NULL
A.	NULL
Spinner	NULL
,	NULL
M.	NULL
Otsyula	NULL
,	NULL
M.	NULL
B.	NULL
McChesney	NULL
,	NULL
and	NULL
M.	NULL
L.	NULL
Marthas	NULL
.	NULL

1995	NULL
.	NULL

Attenuated	NULL
retrovirus	NULL
vaccines	NULL
and	NULL
AIDS	NULL
.	NULL

Science	NULL
270:1218	NULL
.	NULL

Verhoef	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
B.	NULL
Berkhout	NULL
.	NULL

1999	NULL
.	NULL

A	NULL
second-site	NULL
mutation	NULL
that	NULL
restores	NULL
replication	NULL
of	NULL
a	NULL
Tat-defective	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

73	NULL
:	NULL
2781-2789	NULL
.	NULL

Verhoef	NULL
,	NULL
K.	NULL
,	NULL
M.	NULL
Koper	NULL
,	NULL
and	NULL
B.	NULL
Berkhout	NULL
.	NULL

1997	NULL
.	NULL

Determination	NULL
of	NULL
the	NULL
minimal	NULL
amount	NULL
of	NULL
Tat	NULL
activity	NULL
required	NULL
for	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
replication	NULL
.	NULL

Virology	NULL
237:228-236	NULL
.	NULL

Wain-Hobson	NULL
,	NULL
S.	NULL
,	NULL
J.-P.	NULL
Vartanian	NULL
,	NULL
M.	NULL
Henry	NULL
,	NULL
N.	NULL
Chenciner	NULL
,	NULL
R.	NULL
Cheynier	NULL
,	NULL
S.	NULL
Delassus	NULL
,	NULL
L.	NULL
Pedroza	NULL
Martins	NULL
,	NULL
M.	NULL
Sala	NULL
,	NULL
M.	NULL
T.	NULL
Nugeyre	NULL
,	NULL
D.	NULL
GuÃ©tard	NULL
,	NULL
D.	NULL
Klatzmann	NULL
,	NULL
J.-C.	NULL
Gluckman	NULL
,	NULL
W.	NULL
Rozenbaum	NULL
,	NULL
F.	NULL
BarrÃ©-Sinoussi	NULL
,	NULL
and	NULL
L.	NULL
Montagnier	NULL
.	NULL

1991	NULL
.	NULL

LAV	NULL
revisited	NULL
:	NULL
origins	NULL
of	NULL
the	NULL
early	NULL
HIV-1	NULL
isolates	NULL
from	NULL
Institut	NULL
Pasteur	NULL
.	NULL

Science	NULL
252:961-965	NULL
.	NULL

Wei	NULL
,	NULL
P.	NULL
,	NULL
M.	NULL
E.	NULL
Garber	NULL
,	NULL
S.-M.	NULL
Fang	NULL
,	NULL
W.	NULL
H.	NULL
Fisher	NULL
,	NULL
and	NULL
K.	NULL
A.	NULL
Jones	NULL
.	NULL

1998	NULL
.	NULL

A	NULL
novel	NULL
CDK9-associated	NULL
C-type	NULL
cyclin	NULL
interacts	NULL
directly	NULL
with	NULL
HIV-1	NULL
Tat	NULL
and	NULL
mediates	NULL
its	NULL
high-affinity	NULL
,	NULL
loop-specific	NULL
binding	NULL
to	NULL
TAR	NULL
RNA	NULL
.	NULL

Cell	NULL
92:451-462	NULL
.	NULL

Wyand	NULL
,	NULL
M.	NULL
S.	NULL
,	NULL
K.	NULL
H.	NULL
Manson	NULL
,	NULL
M.	NULL
Garcia-Moll	NULL
,	NULL
D.	NULL
Montefiori	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Desrosiers	NULL
.	NULL

1996	NULL
.	NULL

Vaccine	NULL
protection	NULL
by	NULL
a	NULL
triple	NULL
deletion	NULL
mutant	NULL
of	NULL
simian	NULL
immunodeficiency	NULL
virus	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

70:3724-3733	NULL
.	NULL

Xiao	NULL
,	NULL
Y.	NULL
,	NULL
T.	NULL
Kuwata	NULL
,	NULL
T.	NULL
Miura	NULL
,	NULL
M.	NULL
Hayami	NULL
,	NULL
and	NULL
H.	NULL
Shida	NULL
.	NULL

2000	NULL
.	NULL

Dox-dependent	NULL
SIVmac	NULL
with	NULL
tetracycline-inducible	NULL
promoter	NULL
in	NULL
the	NULL
U3	NULL
promoter	NULL
region	NULL
.	NULL

Virology	NULL
269:268-275	NULL
.	NULL

